AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation Science
ErythropoietinReceptors, ErythropoietinErythropoiesisAnemiaPolycythemiaRecombinant ProteinsErythroid Precursor CellsHematocritHemoglobinsErythroblastsReticulocyte CountHematinicsErythrocyte CountLeukemia, Erythroblastic, AcuteJanus Kinase 2Spleen Focus-Forming VirusesKidney Failure, ChronicAnemia, NeonatalInterleukin-3Renal DialysisHematopoietic Stem CellsColony-Forming Units AssaySTAT5 Transcription FactorAnoxiaInjections, SubcutaneousIronPolycythemia VeraBlood TransfusionErythrocytesDoping in SportsMilk ProteinsHypoxia-Inducible Factor 1Cells, CulturedCell LinePhenylhydrazinesBone MarrowBone Marrow CellsFriend murine leukemia virusReticulocytesStem Cell FactorSignal TransductionHematopoiesisPhlebotomyErythrocyte VolumeHypoxia-Inducible Factor 1, alpha SubunitCell DivisionAnemia, HypochromicRNA, MessengerErythroid CellsCell HypoxiaNeuroprotective AgentsFerritinsCell DifferentiationBloodlettingDose-Response Relationship, DrugTime FactorsCobaltGATA1 Transcription FactorErythrocyte TransfusionHypoxia-Inducible Factor-Proline DioxygenasesIron RadioisotopesHematopoietic Cell Growth FactorsKidneyMolecular Sequence DataReceptors, Transferrin
Erythropoietin
Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
Receptors, Erythropoietin
Cell surface proteins that bind erythropoietin with high affinity and trigger intracellular changes influencing the behavior of cells.
Erythropoiesis
The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction.
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
Polycythemia
An increase in the total red cell mass of the blood. (Dorland, 27th ed)
Recombinant Proteins
Proteins prepared by recombinant DNA technology.
Erythroid Precursor Cells
The cells in the erythroid series derived from MYELOID PROGENITOR CELLS or from the bi-potential MEGAKARYOCYTE-ERYTHROID PROGENITOR CELLS which eventually give rise to mature RED BLOOD CELLS. The erythroid progenitor cells develop in two phases: erythroid burst-forming units (BFU-E) followed by erythroid colony-forming units (CFU-E); BFU-E differentiate into CFU-E on stimulation by ERYTHROPOIETIN, and then further differentiate into ERYTHROBLASTS when stimulated by other factors.
Hematocrit
The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value.
Hemoglobins
The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements.
Erythroblasts
Immature, nucleated ERYTHROCYTES occupying the stage of ERYTHROPOIESIS that follows formation of ERYTHROID PRECURSOR CELLS and precedes formation of RETICULOCYTES. The normal series is called normoblasts. Cells called MEGALOBLASTS are a pathologic series of erythroblasts.
Reticulocyte Count
The number of RETICULOCYTES per unit volume of BLOOD. The values are expressed as a percentage of the ERYTHROCYTE COUNT or in the form of an index ("corrected reticulocyte index"), which attempts to account for the number of circulating erythrocytes.
Hematinics
Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias.
Erythrocyte Count
The number of RED BLOOD CELLS per unit volume in a sample of venous BLOOD.
Leukemia, Erythroblastic, Acute
A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.
Janus Kinase 2
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
Spleen Focus-Forming Viruses
Strains of MURINE LEUKEMIA VIRUS that are replication-defective and rapidly transforming. The envelope gene plays an essential role in initiating erythroleukemia (LEUKEMIA, ERYTHROBLASTIC, ACUTE), manifested by splenic foci, SPLENOMEGALY, and POLYCYTHEMIA. Spleen focus-forming viruses are generated by recombination with endogenous retroviral sequences.
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Anemia, Neonatal
The mildest form of erythroblastosis fetalis in which anemia is the chief manifestation.
Interleukin-3
A multilineage cell growth factor secreted by LYMPHOCYTES; EPITHELIAL CELLS; and ASTROCYTES which stimulates clonal proliferation and differentiation of various types of blood and tissue cells.
Renal Dialysis
Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION.
Hematopoietic Stem Cells
Progenitor cells from which all blood cells derive.
Colony-Forming Units Assay
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
STAT5 Transcription Factor
A signal transducer and activator of transcription that mediates cellular responses to a variety of CYTOKINES. Stat5 activation is associated with transcription of CELL CYCLE regulators such as CYCLIN KINASE INHIBITOR P21 and anti-apoptotic genes such as BCL-2 GENES. Stat5 is constitutively activated in many patients with acute MYELOID LEUKEMIA.
Anoxia
Relatively complete absence of oxygen in one or more tissues.
Injections, Subcutaneous
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
Iron
A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN.
Polycythemia Vera
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
Blood Transfusion
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
Erythrocytes
Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.
Doping in Sports
Illegitimate use of substances for a desired effect in competitive sports. It includes humans and animals.
Milk Proteins
The major protein constituents of milk are CASEINS and whey proteins such as LACTALBUMIN and LACTOGLOBULINS. IMMUNOGLOBULINS occur in high concentrations in COLOSTRUM and in relatively lower concentrations in milk. (Singleton and Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed, p554)
Hypoxia-Inducible Factor 1
A basic helix-loop-helix transcription factor that plays a role in APOPTOSIS. It is composed of two subunits: ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR and HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT.
Cells, Cultured
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Cell Line
Established cell cultures that have the potential to propagate indefinitely.
Phenylhydrazines
Diazo derivatives of aniline, used as a reagent for sugars, ketones, and aldehydes. (Dorland, 28th ed)
Bone Marrow
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Bone Marrow Cells
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
Friend murine leukemia virus
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice.
Reticulocytes
Immature ERYTHROCYTES. In humans, these are ERYTHROID CELLS that have just undergone extrusion of their CELL NUCLEUS. They still contain some organelles that gradually decrease in number as the cells mature. RIBOSOMES are last to disappear. Certain staining techniques cause components of the ribosomes to precipitate into characteristic "reticulum" (not the same as the ENDOPLASMIC RETICULUM), hence the name reticulocytes.
Stem Cell Factor
A hematopoietic growth factor and the ligand of the cell surface c-kit protein (PROTO-ONCOGENE PROTEINS C-KIT). It is expressed during embryogenesis and is a growth factor for a number of cell types including the MAST CELLS and the MELANOCYTES in addition to the HEMATOPOIETIC STEM CELLS.
Signal Transduction
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Hematopoiesis
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
Phlebotomy
The techniques used to draw blood from a vein for diagnostic purposes or for treatment of certain blood disorders such as erythrocytosis, hemochromatosis, polycythemia vera, and porphyria cutanea tarda.
Erythrocyte Volume
Volume of circulating ERYTHROCYTES . It is usually measured by RADIOISOTOPE DILUTION TECHNIQUE.
Hypoxia-Inducible Factor 1, alpha Subunit
Hypoxia-inducible factor 1, alpha subunit is a basic helix-loop-helix transcription factor that is regulated by OXYGEN availability and is targeted for degradation by VHL TUMOR SUPPRESSOR PROTEIN.
Cell Division
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Anemia, Hypochromic
Anemia characterized by a decrease in the ratio of the weight of hemoglobin to the volume of the erythrocyte, i.e., the mean corpuscular hemoglobin concentration is less than normal. The individual cells contain less hemoglobin than they could have under optimal conditions. Hypochromic anemia may be caused by iron deficiency from a low iron intake, diminished iron absorption, or excessive iron loss. It can also be caused by infections or other diseases, therapeutic drugs, lead poisoning, and other conditions. (Stedman, 25th ed; from Miale, Laboratory Medicine: Hematology, 6th ed, p393)
RNA, Messenger
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Erythroid Cells
The series of cells in the red blood cell lineage at various stages of differentiation.
Cell Hypoxia
A condition of decreased oxygen content at the cellular level.
Neuroprotective Agents
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.
Ferritins
Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types.
Cell Differentiation
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Bloodletting
Puncture of a vein to draw blood for therapeutic purposes. Bloodletting therapy has been used in Talmudic and Indian medicine since the medieval time, and was still practiced widely in the 18th and 19th centuries. Its modern counterpart is PHLEBOTOMY.
Dose-Response Relationship, Drug
The relationship between the dose of an administered drug and the response of the organism to the drug.
Time Factors
Elements of limited time intervals, contributing to particular results or situations.
Cobalt
A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.
GATA1 Transcription Factor
A GATA transcription factor that is specifically expressed in hematopoietic lineages and plays an important role in the CELL DIFFERENTIATION of ERYTHROID CELLS and MEGAKARYOCYTES.
Erythrocyte Transfusion
The transfer of erythrocytes from a donor to a recipient or reinfusion to the donor.
Hypoxia-Inducible Factor-Proline Dioxygenases
Dioxygenase enzymes that specifically hydroxylate a PROLINE residue on the HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT. They are OXYGEN-dependent enzymes that play an important role in mediating cellular adaptive responses to HYPOXIA.
Iron Radioisotopes
Unstable isotopes of iron that decay or disintegrate emitting radiation. Fe atoms with atomic weights 52, 53, 55, and 59-61 are radioactive iron isotopes.
Hematopoietic Cell Growth Factors
These growth factors comprise a family of hematopoietic regulators with biological specificities defined by their ability to support proliferation and differentiation of blood cells of different lineages. ERYTHROPOIETIN and the COLONY-STIMULATING FACTORS belong to this family. Some of these factors have been studied and used in the treatment of chemotherapy-induced neutropenia, myelodysplastic syndromes, and bone marrow failure syndromes.
Kidney
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
Molecular Sequence Data
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Receptors, Transferrin
Membrane glycoproteins found in high concentrations on iron-utilizing cells. They specifically bind iron-bearing transferrin, are endocytosed with its ligand and then returned to the cell surface where transferrin without its iron is released.

Human, rat, and mouse kidney cells express functional erythropoietin receptors. (1/3892)

BACKGROUND: Erythropoietin (EPO), secreted by fibroblast-like cells in the renal interstitium, controls erythropoiesis by regulating the survival, proliferation, and differentiation of erythroid progenitor cells. We examined whether renal cells that are exposed to EPO express EPO receptors (EPO-R) through which analogous cytokine responses might be elicited. METHODS: Normal human and rat kidney tissue and defined cell lines of human, rat, and mouse kidney were screened, using reverse transcription-polymerase chain reaction, nucleotide sequencing, ligand binding, and Western blotting, for the expression of EPO-R. EPO's effects on DNA synthesis and cell proliferation were also examined. RESULTS: EPO-R transcripts were readily detected in cortex, medulla, and papilla of human and rat kidney, in mesangial (human, rat), proximal tubular (human, mouse), and medullary collecting duct cells (human). Nucleotide sequences of EPO-R cDNAs from renal cells were identical to those of erythroid precursor cells. Specific 125I-EPO binding revealed a single class of high- to intermediate-affinity EPO-Rs in each tested cell line (kD 96 pm to 1. 4 nm; Bmax 0.3 to 7.0 fmol/mg protein). Western blots of murine proximal tubular cell membranes revealed an EPO-R protein of approximately 68 kDa. EPO stimulated DNA synthesis and cell proliferation dose dependently. CONCLUSION: This is the first direct demonstration, to our knowledge, that renal cells possess EPO-Rs through which EPO stimulates mitogenesis. This suggests currently unrecognized cytokine functions for EPO in the kidney, which may prove beneficial in the repair of an injured kidney while being potentially detrimental in renal malignancies.  (+info)

Role of cytokine signaling molecules in erythroid differentiation of mouse fetal liver hematopoietic cells: functional analysis of signaling molecules by retrovirus-mediated expression. (2/3892)

Erythropoietin (EPO) and its cell surface receptor (EPOR) play a central role in proliferation, differentiation, and survival of erythroid progenitors. Signals induced by EPO have been studied extensively by using erythroid as well as nonerythroid cell lines, and various controversial results have been reported as to the role of signaling molecules in erythroid differentiation. Here we describe a novel approach to analyze the EPO signaling by using primary mouse fetal liver hematopoietic cells to avoid possible artifacts due to established cell lines. Our strategy is based on high-titer retrovirus vectors with a bicistronic expression system consisting of an internal ribosome entry site (IRES) and green fluorescent protein (GFP). By placing the cDNA for a signaling molecule in front of IRES-GFP, virus-infected cells can be viably sorted by fluorescence-activated cell sorter, and the effect of expression of the signaling molecule can be assessed. By using this system, expression of cell-survival genes such as Bcl-2 and Bcl-XL was found to enhance erythroid colony formation from colony-forming unit-erythroid (CFU-E) in response to EPO. However, their expression was not sufficient for erythroid colony formation from CFU-E alone, indicating that EPO induces signals for erythroid differentiation. To examine the role of EPOR tyrosine residues in erythroid differentiation, we introduced a chimeric EGFR-EPOR receptor, which has the extracellular domain of the EGF receptor and the intracellular domain of the EPOR, as well as a mutant EGFR-EPOR in which all the cytoplasmic tyrosine residues are replaced with phenylalanine, and found that tyrosine residues of EPOR are essential for erythroid colony formation from CFU-E. We further analyzed the function of the downstream signaling molecules by expressing modified signaling molecules and found that both JAK2/STAT5 and Ras, two major signaling pathways activated by EPOR, are involved in full erythroid differentiation.  (+info)

Iron depletion by phlebotomy with recombinant erythropoietin prior to allogeneic transplantation to prevent liver toxicity. (3/3892)

Iron overload may induce liver toxicity after hematopoietic stem cell transplantation (HSCT), but it is not known if iron depletion prior to HSCT can reduce the risk of severe toxicity in this setting. We used subcutaneous recombinant erythropoietin (EPO) (25 UI/kg) three times a week and phlebotomy once a week, to prevent liver toxicity in a patient with advanced acute leukemia and liver disease due to severe iron overload, previous drug toxicity and hepatitis C viral infection. Over the 9 months prior to allogeneic HSCT, 34 phlebotomies were carried out. Serum ferritin dropped from 2964 to 239 microg/l and the ALT dropped to near normal values. At allogeneic HSCT no liver toxicity was observed, suggesting that iron depletion in the pretransplant period may contribute to reducing transplant-related toxicity in selected cases.  (+info)

Association of plasma fibrinogen concentration with vascular access failure in hemodialysis patients. (4/3892)

BACKGROUND: Elevated plasma fibrinogen is an important risk factor for coronary artery disease in the general population and patients with chronic renal failure. High plasma fibrinogen may trigger thrombus formation in arteriovenous fistulas. We performed a prospective, cohort study to evaluate the association of plasma fibrinogen concentration with vascular access failure in patients undergoing long-term haemodialysis. METHODS: Between September 1989 and October 1995, 144 patients underwent a vascular access operation. In March 1997, 102 patients (56 M, 46 F) who had been followed up for more than 18 months (median; 37 months, range; 18-102 months) were included in the study. The median age of the patients was 52 years (range; 19-78 years). In 35 patients, renal disease was secondary to diabetes mellitus. The type of vascular access was a polytetrafluoroethylene (PTFE) graft in 17 patients. Seventy-seven patients received recombinant human erythropoietin (r-HuEPO) therapy during the follow-up period. Plasma fibrinogen, albumin, total cholesterol, hematocrit, platelets and creatinine were measured at the time of operation. Vascular access failure was defined as the occurrence of complications requiring transluminal angioplasty, thrombolytic therapy or surgical repair. RESULTS: Thirty-eight patients had at least one vascular access failure and the incidence was 0.3 (range; 0-2.4) episodes per patient-year. The survival rate of vascular access was 78% (native fistula; 80%, PTFE graft; 71%) after 12 months and 70% (native fistula; 73%, PTFE graft; 51%) after 24 months. Older age, a PTFE graft, r-HuEPO therapy, higher hematocrit, lower albumin and higher fibrinogen levels were significantly associated with vascular access failure, whereas gender, diabetes mellitus, total cholesterol and platelet count were not. Plasma fibrinogen was inversely correlated with albumin (r=-0.38, P=0.001). The cumulative vascular access survival was significantly lower in patients with high plasma fibrinogen levels (> or = 460 mg/dl) compared with patients with low levels (< 460 mg/dl) (P=0.007). Independent risk factors for vascular access failure analysed by Cox's proportional hazards model were older age (RR; 1.36 by 10-year increment), higher fibrinogen level (RR; 1.20 by 100 mg/dl increment), PTFE graft (RR; 2.28) and r-HuEPO therapy (RR; 3.79). CONCLUSION: High plasma fibrinogen level is an independent risk factor for vascular access failure in haemodialysis patients.  (+info)

Advances in the biological therapy and gene therapy of malignant disease. (5/3892)

Biological and gene therapy of cancer have become important components of clinical cancer research. Advances in this area are based on evidence for the presence of tumor antigens, antitumor immune responses, evasion of host control by tumors, and the recognition of host defense failure in cancer patients. These mechanisms are being corrected or exploited in the development of biological and gene therapy. Over the last decade, 9 biological therapies have received Food and Drug Administration approval, and another 12 appear promising and will likely be approved in the next few years. Our approach to gene therapy has been to allogenize tumors by the direct intratumoral injection of HLA-B7/beta2-microglobulin genes as plasmid DNA in a cationic lipid into patients with malignant melanoma. In four Phase I studies, we found a 36% response by the local injected tumor and a 19% systemic antitumor response. In other cancers, gene transfer, expression, and an intratumoral T-cell response were seen, but no clinical response was seen. A variety of follow-up studies with HLA-B7 and other genes are planned. Evasion of host control is now a major target of gene therapy. Strategies to overcome this include up-regulation of MHC and introduction of cell adhesion molecules into tumor cells, suppression of transforming growth factor and interleukin 10 production by tumor cells, and blockade of the fas ligand-fas interaction between tumor cells and attacking lymphocytes. With these approaches, it seems likely that gene therapy may become the fifth major modality of cancer treatment in the next decade.  (+info)

Identification of the poly(C) binding protein in the complex associated with the 3' untranslated region of erythropoietin messenger RNA. (6/3892)

Hypoxia regulates expression of erythropoietin (EPO), a glycoprotein that stimulates erythrocytosis, at the level of transcription and also possibly at the level of messenger RNA (mRNA) stability. A pyrimidine-rich region within the EPO mRNA 3' untranslated region was implicated in regulation of EPO mRNA stability element and shown to bind protein factors. In the present study we wished to identify the protein factor binding to the pyrimidine-rich sequence in the EPO mRNA stability element. Using mobility shift assays, ultraviolet light cross-linking, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and electroelution of protein factors from the gel slices corresponding to the ribonucleoprotein complexes, we found that two isoforms of a 40 kD poly(C) binding protein (PCBP, also known as alphaCP or hnRNPE), PCBP1, and PCBP2 are present in that complex. In Hep3B or HepG2 cells hypoxia induces neither expression of PCBP nor formation of the ribonucleoprotein complex associated with EPO mRNA that involves PCBP.  (+info)

Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. (7/3892)

We have recently shown that erythropoietin (EPO)-induced hypertension is unrelated to the rise in hematocrit and is marked by elevated cytosolic [Ca+2] and nitric oxide (NO) resistance. The present study was done to determine the effect of EPO on NO production and endothelial NO synthase (eNOS) expression by endothelial cells. Human coronary artery endothelial cells were cultured to subconfluence and then were incubated for 24 hours in the presence of either EPO (0, 5, and 20 U/mL) alone or EPO plus the calcium channel blocker felodipine. The experiments were carried out with quiescent (0.5% FCS) and proliferating (5% FCS) cells. Total nitrate and nitrite, eNOS protein, DNA synthesis (thymidine incorporation), and cell proliferation (cell count) were determined. In addition, NO production in response to acetylcholine stimulation was tested. EPO resulted in a dose-dependent inhibition of basal and acetylcholine-stimulated NO production and eNOS protein expression and also led to a significant dose-dependent stimulation of DNA synthesis in endothelial cells. The inhibitory effects of EPO on NO production and eNOS expression were reversed by felodipine. Thus, EPO downregulates basal and acetylcholine-stimulated NO production, depresses eNOS expression, and stimulates proliferation in isolated human endothelial cells. The suppressive effects of EPO on NO production and on eNOS expression are reversed by calcium channel blockade.  (+info)

Expression of the erythropoietin receptor by trophoblast cellsin the human placenta. (8/3892)

Nonclassical sites of erythropoietin (EPO) and erythropoietin receptor (EPO-R) expression have been described that suggest new physiological roles for this hormone unrelated to erythropoiesis. The recent finding of EPO expression by trophoblast cells in the human placenta prompted us to consider whether these cells also express EPO-R. With use of immunocytochemistry, EPO-R was identified in villous and extravillous cytotrophoblast cells, as well as in the syncytiotrophoblast at all gestational ages. EPO-R was also expressed by cells within the villous core, including endothelial cells of fetoplacental blood vessels. Placental tissues and isolated and immunopurified trophoblast cells, as well as trophoblast-derived choriocarcinoma Jar cells, expressed immunoreactive EPO-R on Western blot. EPO-R mRNA was also detected in the same placental tissues and trophoblast cells by nested-primer reverse transcription-polymerase chain reaction. Finally, EPO-R was functional insofar as the receptor was phosphorylated on tyrosine residues in response to exogenous EPO treatment of cultured trophoblast or Jar cells. Thus, the present findings support the hypothesis that trophoblast cells of the human placenta express EPO-R. In view of these results, taken together with previous work demonstrating EPO expression by the same cells, an autocrine role for this hormone in the survival, proliferation, or differentiation of placental trophoblast cells is proposed.  (+info)

SciCombinator - Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in...
Comments, concepts and statistics about Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men.
http://scicombinator.com/articles/256664
recombinant human erythropoietin, recombinant human erythropoietin wholesale for sale page30 in Tradezz.comrecombinant human erythropoietin, recombinant human erythropoietin wholesale for sale page30 in Tradezz.com
Looking for recombinant human erythropoietin? Here you can find the lowest price products about recombinant human erythropoietin. We Provide for you about recombinant human erythropoietin page30
http://www.tradezz.com/recombinant-human-erythropoietin_0_30/
Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury<...
TY - JOUR. T1 - Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. AU - Junk, Anna. AU - Mammis, Antonios. AU - Savitz, Sean I.. AU - Singh, Manjeet. AU - Roth, Steven. AU - Malhotra, Samit. AU - Rosenbaum, Pearl S.. AU - Cerami, Anthony. AU - Brines, Michael. AU - Rosenbaum, Daniel M.. PY - 2002/8/1. Y1 - 2002/8/1. N2 - Erythropoietin (EPO) plays an important role in the brains response to neuronal injury. Systemic administration of recombinant human EPO (rhEPO) protects neurons from injury after middle cerebral artery occlusion, traumatic brain injury, neuroinflammation, and excitotoxicity. Protection is in part mediated by antiapoptotic mechanisms. We conducted parallel studies of rhEPO in a model of transient global retinal ischemia induced by raising intraocular pressure, which is a clinically relevant model for retinal diseases. We observed abundant expression of EPO receptor (EPO-R) throughout the ischemic retina. Neutralization of endogenous ...
https://miami.pure.elsevier.com/en/publications/erythropoietin-administration-protects-retinal-neurons-from-acute
A Review of the Efficacy of Erythropoietin Alfa Treatment for Chemotherapy-Induced Anemia | Prized WritingA Review of the Efficacy of Erythropoietin Alfa Treatment for Chemotherapy-Induced Anemia | Prized Writing
he National Anemia Action Council states that about 3.4 million Americans are anemic, with causes ranging from serious chronic illnesses to simple dietary insufficiencies (1). Common symptoms include weakness, pallor, tachycardia, shortness of breath, dizziness, headache, chest pain, and numbness in the extremities (1). Since the late 1990s, recombinant erythropoietin has been used to treat anemic patients, including cancer patients whose anemia has been caused by chemotherapy (2).. Recombinant erythropoietin is also known as epoetin alfa, or EPO, a glycoprotein made by transplanting the human erythropoietin gene into the ovary cells of a Chinese hamster species (2). Due to its relative novelty in the research community, older and newer studies are very similar in their findings that erythropoietin effectively raises hemoglobin levels in anemic patients. Current research, however, is focused on quantifying hemoglobin concentration increases from erythropoietin treatment, exploring possible ...
http://prizedwriting.ucdavis.edu/review-efficacy-erythropoietin-alfa-treatment-chemotherapy-induced-anemia
Acute normobaric hyperoxia transiently attenuates plasma erythropoietin concentration in healthy males : evidence against the ...Acute normobaric hyperoxia transiently attenuates plasma erythropoietin concentration in healthy males : evidence against the ...
Aim: The purpose of the present study was to evaluate the normobaric oxygen paradox theory by investigating the effect of a 2-h normobaric O(2) exposure on the concentration of plasma erythropoietin (EPO). Methods: Ten healthy males were studied twice in a single-blinded counterbalanced crossover study protocol. On one occasion they breathed air (NOR) and on the other 100% normobaric O(2) (HYPER). Blood samples were collected Pre, Mid and Post exposure; and thereafter, 3, 5, 8, 24, 32, 48, 72 and 96 h, and 1 and 2 weeks after the exposure to determine EPO concentration. Results: The concentration of plasma erythropoietin increased markedly 8 and 32 h after the NOR exposure (approx. 58% and approx. 52%, respectively, P , 0.05) as a consequence of its natural diurnal variation. Conversely, the O(2) breathing was followed by approx. 36% decrement of EPO 3 h after the exposure (P , 0.05). Moreover, EPO concentration was significantly lower in HYPER than in the NOR condition 3, 5 and 8 h after the ...
http://kth.diva-portal.org/smash/record.jsf?pid=diva2:439503
The effect of post-injury erythropoietin administration on mortality and Glasgow outcome scales of patients with traumatic...The effect of post-injury erythropoietin administration on mortality and Glasgow outcome scales of patients with traumatic...
The effect of post-injury erythropoietin administration on mortality and Glasgow outcome scales of patients with traumatic brain injury: A metaanalysis., Faye B Garciano, Perry N N
http://www.alliedacademies.org/articles/the-effect-of-postinjury-erythropoietin-administration-on-mortality-and-glasgow-outcome-scales-of-patients-with-traumatic-brain-in-8316.html
1990 - Subcutaneous recombinant human erythropoietin decreased anemia in predialysis patients with chronic renal...1990 - Subcutaneous recombinant human erythropoietin decreased anemia in predialysis patients with chronic renal...
Recombinant human erythropoietin (EPO), given intravenously, or even better, subcutaneously, represents a major advance in treating patients with end-stage renal failure. It has been studied most frequently in patients on hemodialysis and has been shown to increase hemoglobin levels, improve quality of life, and permit avoidance of transfusion with its concomitant risk of infection, iron overload, and sensitization (1). The major side effects of the medication have been hypertension and flu-like symptoms. Subcutaneous EPO can be self-administered and may require a lower dose than intravenous EPO (unfortunately, the mean maintenance dose of erythropoietin in this study was not indicated). The authors found no difference in hypertension between the 2 groups, and no unexpected side effects were reported. There has been concern that the increase in hematocrit in predialysis patients treated with EPO may be associated with acceleration of renal failure. Other studies have found no change in the ...
http://acpjc.org/Content/114/1/issue/ACPJC-1991-114-1-011.htm
Stimulation of erythropoiesis by in vivo gene therapy: physiologic consequences of transfer of the human erythropoietin gene to...Stimulation of erythropoiesis by in vivo gene therapy: physiologic consequences of transfer of the human erythropoietin gene to...
Erythropoietin (Epo), a 30.4-kD glycoprotein, is the principal regulator of erythropoiesis. To evaluate the concept that in vivo gene transfer might be used as an alternative to recombinant human Epo (rhEpo) in applications requiring a 1- to 3-week stimulation of erythropoiesis, the replication-deficient recombinant adenovirus AdMLP.Epo was constructed by deleting the majority of E1 from adenovirus type 5, and replacing E1 with an expression cassette containing the adenovirus type 5 major late promoter (MLP) and the human Epo gene, including the 32 cis-acting hypoxia response element. In vitro studies showed that infection of the human hepatocyte cell line Hep3B with AdMLP.Epo resulted in a 15-fold increase in Epo production in 24 hours that was enhanced to 116-fold in the presence of a hypoxic stimulus. One-time in vivo administration of AdMLP.Epo (7 x 10(9) plaque-forming units/kg) to the peritoneum of cotton rats caused a marked increase in red blood cell production, with a 2.6-fold increase ...
https://ashpublications.org/blood/article/84/9/2946/172923/Stimulation-of-erythropoiesis-by-in-vivo-gene
The expression system was used to create recombinant human erythropoietin, a - BET-bromodomain inhibition researchThe expression system was used to create recombinant human erythropoietin, a - BET-bromodomain inhibition research
The expression system was used to create recombinant human erythropoietin, a protein synthesized by the adult kidney and responsible for the regulation of red blood cell production. of recombinant EPO and increase the activity of TG-101348 this protein Yeasts have long been a model organism for biochemical and genetic studies because of the advantages they offer compared to bacterial systems, including the ease with which they can cultured and managed, and the fact that they share several important biological characteristics with eukaryotic cells, such as splicing and other processes involved in post-translational modifications. Several yeast species have been used to generate recombinant proteins, including and (examined in B?er offers similar advantages to other yeasts, and are preferred as the overall length of the mannose outer chains is shorter than in (Kang and construction of the gene The entire human erythropoietin gene was constructed using the Splicing by Overlap-Extension by PCR ...
http://healthandwellnesssource.org/the-expression-system-was-used-to-create-recombinant-human-erythropoietin-a/
Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm...Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm...
In the present investigation, we studied the effect of recombinant human erythropoietin (r-HuEPO) on serum malondialdehyde (MDA) as an index of lipid peroxidation, related to iron-catalyzed free radical reaction and erythrocyte superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) activities in very-low-birth weight (VLBW) infants. Forty premature infants, at gestational ages were less than 33 weeks and birthweights were less than 1,500 g, were enrolled in the study. The study population was randomly divided into 2 groups. Twenty infants in Group 1 (treatment group) were given r-HuEPO, and 20 infants in Group 2 served as the control. r-HuEPO treatment (750 U/kg a week) was initiated on the 10th day of life and continued for 6 weeks. Preterm infants given erythrocyte transfusions during the study were excluded from the results. Serum ferritin and MDA levels, and erythrocyte superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) activities were analyzed ...
https://avesis.ege.edu.tr/yayin/45cc3f01-3d7f-4388-9801-ea8213dea4c6/effect-of-recombinant-human-erythropoietin-administration-on-lipid-peroxidation-and-antioxidant-enzymes-activities-in-preterm-infants
Macrophages as novel targets for erythropoietin | HaematologicaMacrophages as novel targets for erythropoietin | Haematologica
Background Our original demonstration of immunomodulatory effects of erythropoietin in multiple myeloma, led us to the search of the cells in the immune system that are direct targets to erythropoietin. The finding that lymphocytes do not express erythropoietin receptors, has led to the hypothesis that other cells act as direct targets and thus mediate the erythropoietin effects. Having found erythropoietin effects on dendritic cells thus led to the question of whether macrophages act as target cells to erythropoietin. Design and Methods EPO effects on macrophages were investigated both in-vivo and in-vitro. The in-vivo studies were performed on splenic macrophages and inflammatory peritoneal macrophages, in recombinant human erythropoietin -treated, compared to untreated mice, as well as in transgenic mice over-expressing human erythropoietin (tg6), compared to their control wild type counterparts. The in-vitro effects of erythropoietin on macrophage surface markers and function were ...
http://www.haematologica.org/content/early/2010/06/30/haematol.2010.025015
Erythropoietin, a Novel Versatile Player Regulating Energy Metabolism beyond the Erythroid SystemErythropoietin, a Novel Versatile Player Regulating Energy Metabolism beyond the Erythroid System
1. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83:59-67 2. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. The Journal of biological chemistry. 1977;252:5558-64 3. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC. et al. Cloning and expression of the human erythropoietin gene. Proceedings of the National Academy of Sciences of the United States of America. 1985;82:7580-4 4. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A. et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313:806-10 5. Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert reviews in molecular medicine. 2008;10:e36. doi:10.1017/S1462399408000860 6. Teng R, Gavrilova O, Suzuki N, Chanturiya T, Schimel D, Hugendubler L. et ...
http://www.ijbs.com/v10p0921.htm
Recombinant Human Erythropoietin Treatment in Pre-Dialysis PatientsA Double-Blind Placebo-Controlled Trial | Annals of Internal...Recombinant Human Erythropoietin Treatment in Pre-Dialysis PatientsA Double-Blind Placebo-Controlled Trial | Annals of Internal...
Study Objective: To determine the efficacy and safety of recombinant human erythropoietin (r-HuEPO) in predialysis renal patients.. Design: Randomized, double-blind, placebo-controlled trial for 8 weeks.. Setting: Inpatient and outpatient facility in the Clinical Research Center of a university-based hospital.. Patients: Fourteen adult subjects with renal insufficiency (mean serum creatinine, 473 µmol/L ± 61 [6.2 µ 0.8 mg/dL] ) and anemia (mean hematocrit, 0.27 ± 0.01).. Interventions: Recombinant human erythropoietin, 50, 100, or 150 IU/kg body weight or placebo given intravenously three times per week.. Measurements and Main Results: Subjects who received active r-HuEPO showed a dose-dependent rise in hematocrit; mean hematocrit increased 41% from 0. 27 ± 0.01 to 0.38 ± 0.01. At the same time, erythrocyte mass rose 43% from 13.7 ± 0.6 mL/kg in the baseline state to 19.6 ± 1.0 mL/kg after treatment. Maximal oxygen consumption during exercise increased 9% from 16.0 mL/min · kg ± 1.8 to ...
http://annals.org/aim/article-abstract/702853/recombinant-human-erythropoietin-treatment-pre-dialysis-patients-double-blind-placebo
Validation of whole-blood transcriptome signature during microdose recombinant human erythropoietin (rHuEpo) administration |...Validation of whole-blood transcriptome signature during microdose recombinant human erythropoietin (rHuEpo) administration |...
Recombinant human erythropoietin (rHuEpo) can improve human performance and is therefore frequently abused by athletes. As a result, the World Anti-Doping Agency (WADA) introduced the Athlete Biological Passport (ABP) as an indirect method to detect blood doping. Despite this progress, challenges remain to detect blood manipulations such as the use of microdoses of rHuEpo. Forty-five whole-blood transcriptional markers of rHuEpo previously derived from a high-dose rHuEpo administration trial were used to assess whether microdoses of rHuEpo could be detected in 14 trained subjects and whether these markers may be confounded by exercise (n = 14 trained subjects) and altitude training (n = 21 elite runners and n = 4 elite rowers, respectively). Differential gene expression analysis was carried out following normalisation and significance declared following application of a 5% false discovery rate (FDR) and a 1.5 fold-change. Adaptive model analysis was also applied to incorporate these markers for the
https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-017-4191-7/tables/3
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues - The ASCO PostThe WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues - The ASCO Post
A. A male patient with JAK2 V617F mutation, hemoglobin of 13.5 g/dL, and subnormal serum erythropoietin level. B. A male patient with JAK2 V617F mutation, hemoglobin of 16.5 g/dL, and subnormal serum erythropoietin level. C. A patient with JAK2 V617F mutation, hemoglobin of 18.5 g/dL, and subnormal serum erythropoietin level. D. A and B are correct. Question 2 Which of the following is a minor criterion to facilitate the diagnosis of polycythemia vera?. A. Elevated hematocrit of , 48% in women and , 49% in men. B. Elevated hemoglobin of , 16.0 g/dL in women and , 16.5 g/dL in men. C. Bone marrow biopsy showing age-adjusted hypercellularity with panmyelosis and pleomorphic mature megakaryocytes. D. Subnormal serum erythropoietin level. Question 3 Which of the following is a well-described bone marrow characteristic of polycythemia vera?. A. Unilineage erythroid hyperplasia. B. Age-adjusted hypercellularity. C. Pleomorphic immature megakaryocytes. D. All of the above. Question 4 Which of the ...
https://ascopost.com/issues/november-10-2018/the-who-classification-of-tumors-of-hematopoietic-and-lymphoid-tissues/
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues - The ASCO PostThe WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues - The ASCO Post
A. A male patient with JAK2 V617F mutation, hemoglobin of 13.5 g/dL, and subnormal serum erythropoietin level. B. A male patient with JAK2 V617F mutation, hemoglobin of 16.5 g/dL, and subnormal serum erythropoietin level. C. A patient with JAK2 V617F mutation, hemoglobin of 18.5 g/dL, and subnormal serum erythropoietin level. D. A and B are correct. Question 2 Which of the following is a minor criterion to facilitate the diagnosis of polycythemia vera?. A. Elevated hematocrit of , 48% in women and , 49% in men. B. Elevated hemoglobin of , 16.0 g/dL in women and , 16.5 g/dL in men. C. Bone marrow biopsy showing age-adjusted hypercellularity with panmyelosis and pleomorphic mature megakaryocytes. D. Subnormal serum erythropoietin level. Question 3 Which of the following is a well-described bone marrow characteristic of polycythemia vera?. A. Unilineage erythroid hyperplasia. B. Age-adjusted hypercellularity. C. Pleomorphic immature megakaryocytes. D. All of the above. Question 4 Which of the ...
https://www.ascopost.com/issues/november-10-2018/the-who-classification-of-tumors-of-hematopoietic-and-lymphoid-tissues/
The Effect of Recombinant Human Erythropoietin on Neurovasculature Repair after Focal Ischemic Stroke in Neonatal Rats |...The Effect of Recombinant Human Erythropoietin on Neurovasculature Repair after Focal Ischemic Stroke in Neonatal Rats |...
Animal Model. Neonatal Wistar rats were randomly divided into three groups: 1) no-stroke control, 2) saline control, and 3) rhEPO treatment. The surgical procedure of whisker-barrel cortex ischemia in neonatal rats followed similar methods as described previously (Wei et al., 2006). In brief, postnatal day 7 (P7) pups were anesthetized by hypothermia. Hypothermia anesthesia was chosen because many of the drugs used to anesthetize adult animals provided inadequate anesthesia for neonates or were associated with problems such as excessively high mortality (Danneman and Mandrell, 1997). In this regard, hypothermia (immersion in ice) has been judged as a humane, safe, and effective anesthesia method for survival surgeries of neonatal rats (Danneman and Mandrell, 1997). The hypothermia procedure was kept the same for all pups in different experimental groups. Pups were placed in a noninvasive head-holder to allow for a 2.5- to 3.0-mm-diameter craniectomy through the right parietal skull. The ...
http://jpet.aspetjournals.org/content/322/2/521.long
Recombinant Human Erythropoietin in Cancer-Related AnemiaRecombinant Human Erythropoietin in Cancer-Related Anemia
The clinical development of recombinant human erythropoietin (rHuEPO) has had a remarkable impact on the clinical practice of oncology. A decade ago, randomized, placebo-controlled trials in anemic cancer patients demonstrated that rHuEPO resulted in an improvement in hemoglobin and hematocrit, a reduction in transfusion requirements, and improvement in quality-of-life (QOL) end points. Based on these trials, recombinant erythropoietin was approved for the treatment of anemia in patients with nonmyeloid malignancies in whom the anemia was caused by the effect of chemotherapy.
https://www.cancernetwork.com/view/recombinant-human-erythropoietin-cancer-related-anemia
Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients<...Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients<...
TY - JOUR. T1 - Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. AU - Cody, June D. AU - Daly, Conal. AU - Campbell, Marion K. AU - Khan, Izhar. AU - Rabindranath, Kannaiyan S. AU - Vale, Luke. AU - Wallace, Sheila A. AU - MacLeod, Alison M. AU - Grant, Adrian M. AU - Pennington, Susan AU - Nistor, Ionut. AU - Bolignano, Davide. AU - Webster, Angela C. PY - 2005/7/20. Y1 - 2005/7/20. N2 - Background Treatment with recombinant human erythropoietin (rHu EPO) in dialysis patients has been shown to be highly effective in terms of correcting anaemia and improving quality of life. There is debate concerning the benefits of rHu EPO use in pre-dialysis patients which may accelerate the deterioration of renal function. However the opposing view is that if rHu EPO is as effective in pre-dialysis patients, improving the patients sense of well-being may result in the onset of dialysis being delayed.Objectives To assess the effects of rHu EPO use in pre-dialysis ...
https://abdn.pure.elsevier.com/en/publications/recombinant-human-erythropoietin-for-chronic-renal-failure-anaemi
Cellular and molecular mechanisms regulating the hepatic erythropoietin expression: a role for Interleukin-6 | superhumangearCellular and molecular mechanisms regulating the hepatic erythropoietin expression: a role for Interleukin-6 | superhumangear
Cellular and molecular mechanisms regulating the hepatic erythropoietin expression during acute-phase response: a role for IL-6 Ramadori P, Ahmad G, Ramadori G. Source Department of Gastroenterology and Endocrinology, Center of Internal Medicine, University of Göttingen, Göttingen, Germany. Abstract The source of circulating erythropoietin (EPO), the mediators and the mechanisms involved in the upregulation of EPO…
https://superhumangear.wordpress.com/2011/11/23/cellular-and-molecular-mechanisms-regulating-the-hepatic-erythropoietin-expression-a-role-for-interleukin-6/
Recombinant human erythropoietin stimulates vasculogenesis and wound healing in a patient with systemic sclerosis complicated...
TY - JOUR. T1 - Recombinant human erythropoietin stimulates vasculogenesis and wound healing in a patient with systemic sclerosis complicated by severe skin ulcers. AU - Ferri, C.. AU - Giuggioli, D.. AU - Manfredi, A.. AU - Quirici, N.. AU - Scavullo, C.. AU - Colaci, M.. AU - Gianelli, U.. AU - Lambertenghi Deliliers, G.. AU - Del Papa, N.. PY - 2010/12. Y1 - 2010/12. N2 - Systemic sclerosis (SSc) is often complicated by severe skin ulcers that are unresponsive to traditional treatments. Vascular alterations are responsible for the ischaemic features of the disease in both the skin and visceral organs. Defective neoangiogenesis correlates with an abnormally reduced quantity of circulating endothelial progenitor cells (EPCs) caused by impaired maturation potential and proliferative capacity of bone-marrow endothelial stem cells. We report a patient with nonhealing cutaneous ulcers successfully treated with recombinant human erythropoietin (rHuEPO). The possible biological effects of this drug ...
https://moh-it.pure.elsevier.com/en/publications/recombinant-human-erythropoietin-stimulates-vasculogenesis-and-wo
Inactivation of erythropoietin leads to defects in cardiac morphogenesis | DevelopmentInactivation of erythropoietin leads to defects in cardiac morphogenesis | Development
Erythropoietin is an essential growth factor that promotes survival, proliferation, and differentiation of mammalian erythroid progenitor cells. Erythropoietin(−/−) and erythropoietin receptor(−/−) mouse embryos die around embryonic day 13.5 due, in part, to failure of erythropoiesis in the fetal liver. In this study, we demonstrated a novel role of erythropoietin and erythropoietin receptor in cardiac development in vivo. We found that erythropoietin receptor is expressed in the developing murine heart in a temporal and cell type-specific manner: it is initially detected by embryonic day 10.5 and persists until day 14.5. Both erythropoietin(−/−) and erythropoietin receptor(−/−) embryos suffered from ventricular hypoplasia at day 12-13 of gestation. This defect appears to be independent from the general state of hypoxia and is likely due to a reduction in the number of proliferating cardiac myocytes in the ventricular myocardium. Cell proliferation assays revealed that ...
http://dev.biologists.org/content/126/16/3597
Effects of theophylline on erythropoietin production in normal subjects in patients with erythrocytosis after renal...Effects of theophylline on erythropoietin production in normal subjects in patients with erythrocytosis after renal...
Effects of theophylline on erythropoietin production in normal subjects in patients with erythrocytosis after renal transplantation
http://www.readabstracts.com/Health/Effects-of-theophylline-on-erythropoietin-production-in-normal-subjects-in-patients-with-erythrocyto.html
Effects Of Recombinant Human Erythropoietin On Platelet Activation In Acute Myocardial Infarction: Results Of A Double-Blind,...
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
http://pubmedcentralcanada.ca/pmcc/articles/PMC2838229/
Effect of inhibitors of oxidative phosphorylation on erythropoietin mRNA in isolated perfused rat kidneys. - Target Discovery...
We have used RNase protection to measure oxygen-dependent changes in erythropoietin (EPO) mRNA in isolated perfused kidneys and to compare the effect of hypoxia with the response to inhibitors of oxidative phosphorylation. In well-oxygenated kidneys perfused for 2 h at 12 ml/min, with hematocrit of 0.09 +/- 0.005 and PO2 of 443 +/- 67 mmHg, EPO mRNA levels were similar to the baseline levels measured in nonperfused contralateral kidneys from the same animals. When perfusions were performed under identical conditions but at a PO2 of 32 +/- 4 mmHg, EPO mRNA increased approximately 16-fold. In contrast, graded concentrations of cyanide (10, 100, and 300 microM and 1 mM), antimycin (0.01, 0.1, 0.5, and 1 microM), and oligomycin (0.01, 0.1, and 1 microM) did not alter EPO mRNA in well-oxygenated perfused kidneys. However, in kidneys perfused at low PO2 with a high concentration of each inhibitor, EPO mRNA levels were increased, demonstrating that the ability to respond to hypoxia was retained. Thus
https://www.tdi.ox.ac.uk/publications/13791
Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats |...Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats |...
Background: Ischemia/reperfusion (I/R) injury is an important cause of renal graft dysfunction. Increases in cold and warm ischemia times lead to a higher risk of early posttransplant complications including delayed graft function and acute rejection. Moreover, prolonged cold ischemia is a predictor of long-term graft loss in kidney transplant patients. Methods: Darbepoetin alfa (DA) and carbamylated nonerythropoietic derivative of erythropoietin (CEPO) protective effects were evaluated in a model of I/R injury after kidney transplantation in both syngeneic and allogeneic combinations. The effects of wortmannin (phosphorylated Akt [p-Akt] inhibitor) administration were also investigated. Serum creatinine was evaluated at 16, 24, 48 hr and at 4 and 7 days posttransplant. Animals were killed 24 hr or 7 days after transplant and kidneys were processed for histological analysis, immunohistochemistry assessment of erythropoietin receptor (EPOR) and β-common chain receptor expression, granulocyte ...
https://air.unimi.it/handle/2434/332163
Prognostic significance of erythropoietin expression in human renal cell carcinoma - Surrey Research Insight Open AccessPrognostic significance of erythropoietin expression in human renal cell carcinoma - Surrey Research Insight Open Access
Michael, A, Politi, E, Havranek, E, Corbishley, C, Karapanagiotou, L, Anderson, C, Relph, K, Syrigos, KN and Pandha, H (2007) Prognostic significance of erythropoietin expression in human renal cell carcinoma ...
http://epubs.surrey.ac.uk/210372/
THE EFFECT OF EXOGENOUS ERYTHROPOIETIN UPON ERYTHROPOIESIS IN RADIATION- INDUCED ANEMIC RATS
Experiments were performed to test the hypothesis that rats could be made permanently anemic by repeated mixed gamma-neutron irradiations, and that once the maintenance of normal circulatory red cell concentration was lost, the administration of exogenous erythropoietin could not restore the production of red cells to normal levels. Rats were exposed to 9 periodic doses of 150 rads mixed gamma-neutron radiation or to 4 periodic doses of 300 rads. Hematocrits and erythrocyte counts obtained for 100 days or more after the final radiation exposure showed a significant reduction in erythrocyte production. This permanent anemia was not ameliorated by the treatment with 5 daily doses of either 5 units or 25 units of erythropoietin. These findings appear to strengthen the hypothesis that the permanent anemia is caused by a reduced capability for cellular proliferation due to accumulation of residual injury in stem cells.
http://www.dtic.mil/docs/citations/AD0688767
Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice | Science Translational...Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice | Science Translational...
Although rhEPO treatment is beneficial for CKD patients with renal anemia, several problems remain to be addressed. First, the increasing number of CKD patients is expanding the demand for rhEPO treatment, which, in turn, increases the total cost of this therapy. Second, it is difficult to physiologically control renal anemia using rhEPO treatment. The intermittent administration of rhEPO causes fluctuations in hemoglobin concentrations (3), which is associated with an increased incidence of cardiovascular events (23). In addition, the target hemoglobin concentration for rhEPO treatment remains controversial, and hemoglobin concentrations in most patients are lower than those observed in healthy subjects (24). The physiological control of renal anemia based on a stable, normal range of hemoglobin concentrations may help in the treatment of CKD patients.. hiPSCs/ESCs are potential cell sources for regenerative medicine. Here, we generated EPO-producing cells from hiPSCs/ESCs and miPSCs/ESCs. ...
https://stm.sciencemag.org/content/9/409/eaaj2300
Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice | Science Translational...Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice | Science Translational...
Although rhEPO treatment is beneficial for CKD patients with renal anemia, several problems remain to be addressed. First, the increasing number of CKD patients is expanding the demand for rhEPO treatment, which, in turn, increases the total cost of this therapy. Second, it is difficult to physiologically control renal anemia using rhEPO treatment. The intermittent administration of rhEPO causes fluctuations in hemoglobin concentrations (3), which is associated with an increased incidence of cardiovascular events (23). In addition, the target hemoglobin concentration for rhEPO treatment remains controversial, and hemoglobin concentrations in most patients are lower than those observed in healthy subjects (24). The physiological control of renal anemia based on a stable, normal range of hemoglobin concentrations may help in the treatment of CKD patients.. hiPSCs/ESCs are potential cell sources for regenerative medicine. Here, we generated EPO-producing cells from hiPSCs/ESCs and miPSCs/ESCs. ...
https://stm.sciencemag.org/content/9/409/eaaj2300.full
Patent US6376218 - Expression system for producing recombinant human erythropoietin, method for ... - Google PatentsPatent US6376218 - Expression system for producing recombinant human erythropoietin, method for ... - Google Patents
The present invention provides an expression system for producing recombinant human erythropoietin (rhEPO) exhibiting biological activity and immunochemical properties of the native human erythropoietin (hEPO). Also provided is an improved method for purifying rhEPO from culture medium by two-step column chromatography.
http://www.google.com/patents/US6376218?dq=5958006
Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial...Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial...
BACKGROUND: Preclinical studies and pilot clinical trials have shown that high-dose erythropoietin (EPO) reduces infarct size in acute myocardial infarction. We investigated whether a single high-dose of EPO administered immediately after reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) would limit infarct size. METHODS: A total of 110 patients undergoing successful primary coronary intervention for a first STEMI was randomized to receive standard care either alone (n = 57) or combined with intravenous administration of 1,000 U/kg of epoetin β immediately after reperfusion (n = 53). The primary end point was infarct size assessed by gadolinium-enhanced cardiac magnetic resonance after 3 months. Secondary end points included left ventricular (LV) volume and function at 5-day and 3-month follow-up, incidence of microvascular obstruction (MVO), and safety. RESULTS: Erythropoietin significantly decreased the incidence of MVO (43.4% vs 65.3% in the control group, P = .03) and
http://hal.univ-brest.fr/hal-00811692
Recombinant erythropoietin in humans has a prolonged effect on circulating erythropoietin isoform distribution - Danish...Recombinant erythropoietin in humans has a prolonged effect on circulating erythropoietin isoform distribution - Danish...
The membrane-assisted isoform immunoassay (MAIIA) quantitates erythropoietin (EPO) isoforms as percentages of migrated isoforms (PMI). We evaluated the effect of recombinant human EPO (rhEPO) on the distribution of EPO isoforms in plasma in a randomized, placebo-controlled, double-blinded, cross-over study. 16 healthy subjects received either low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13); high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13); or placebo on all days. PMI on days 4, 11 and 25 was determined by interaction of N-acetyl glucosamine with the glycosylation dependent desorption of EPO isoforms. At day 25, plasma-EPO in both rhEPO groups had returned to values not different from the placebo group. PMI with placebo, reflecting the endogenous EPO isoforms, averaged 82.5 (10.3) % (mean (SD)). High-dose Epoetin beta decreased PMI on days 4 and 11 to 31.0 (4.2)% (p,0.00001) and 45.2 (7.3)% (p,0.00001). Low-dose Epoetin beta decreased ...
http://www.forskningsdatabasen.dk/catalog/272266036
Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia - Nuffield Department of...
Erythropoietin (EPO) mRNA levels were measured by ribonuclease (RNase) protection in organs from unstimulated rats and from animals after normobaric hypoxia or hemorrhagic anemia. Both liver and kidney responded to stimulation with large increases in EPO mRNA, but the response characteristic to graded stimulation was different. The liver responded poorly to mild normobaric hypoxia, accounting for only 2 ± 1% of total EPO mRNA at 11% O2, but hepatic EPO mRNA levels increased steeply with more severe hypoxia so that at 7.5% O2 the liver contributed to 33 ± 7% of the total. After hemorrhagic anemia, the liver also responded more strongly to more severe stimulation, but at all points it accounted for a significant proportion of total EPO mRNA, contributing 18 ± 6% after removal of 2.5 ml (hematocrit 37.2 ± 1.3%), increasing to 37 ± 14% after venesection of 10.5 ml (hematocrit 15.8 ± 0.8%). Studies of EPO mRNA in other organs confirmed that EPO production outside the liver and kidney were
https://www.ndm.ox.ac.uk/publications/799616
Clinical validation of an RIA for natural and recombinant erythropoietin in serun and plasma<...Clinical validation of an RIA for natural and recombinant erythropoietin in serun and plasma<...
TY - JOUR. T1 - Clinical validation of an RIA for natural and recombinant erythropoietin in serun and plasma. AU - Goldberg, Mark A.. AU - Schneider, Thomas J.. AU - Khan, Shaista. AU - Petersen, John R.. PY - 1993. Y1 - 1993. N2 - A sensitive radioimmunoassay (RIA) for the detection of erythropoietin (EPO) was developed using antibody directed against EPO from human urine. With 100 μL of sample, the assay is sensitive to 7 U/L, well below the mean EPO level in normal males (15.1 ± 3.5 U/L) or females (15.4 ± 4.8 U/L). Dilutions of a variety of human serum samples show a parallel relationship with the standard EPO. Clinical validation of the RIA was confirmed by appropriate increases or decreases of EPO levels in various types of anemia and polycythemia. Serum EPO levels were also measured in volunteers participating in an autologous blood donation study. The RIA proved to eb quite sensitve, detecting small increases even after a single unit phlebotomy. This RIA of human EPO meets all the ...
https://researchexperts.utmb.edu/en/publications/clinical-validation-of-an-ria-for-natural-and-recombinant-erythro
Monitoring recombinant human erythropoietin abuse among athletes - Institute of Nano Electronic Engineering
Abstract - The illegal administration of recombinant human erythropoietin (rHuEPO) among athletes is largely preferred over blood doping to enhance stamina. The advent of recombinant DNA technology allowed the expression of EPO-encoding genes in several eukaryotic hosts to produce rHuEPO, and today these performance-enhancing drugs are readily available. As a mimetic of endogenous EPO (eEPO), rHuEPO augments the oxygen carrying capacity of blood. Thus, monitoring the illicit use of rHuEPO among athletes is crucial in ensuring an even playing field and maintaining the welfare of athletes. A number of rHuEPO detection methods currently exist, including measurement of hematologic parameters, gene-based detection methods, glycomics, use of peptide markers, electrophoresis, isoelectric focusing (IEF)-double immunoblotting, aptamer/antibody-based methods, and lateral flow tests. This review gleans these different strategies and highlights the leading molecular recognition elements that have potential ...
https://inee.unimap.edu.my/monitoring-recombinant-human-erythropoietin-abuse-among-athletes.html?shared=email&msg=fail
Robust increases in erythropoietin production by the hypoxic fetus is a response to protect the brain and other vital organs<...
TY - JOUR. T1 - Robust increases in erythropoietin production by the hypoxic fetus is a response to protect the brain and other vital organs. AU - Teramo, Kari A.. AU - Klemetti, Miira M.. AU - Widness, John A.. PY - 2018/12. Y1 - 2018/12. KW - AMNIOTIC-FLUID. KW - PLASMA ERYTHROPOIETIN. KW - IMMUNOREACTIVE ERYTHROPOIETIN. KW - CEREBROSPINAL-FLUID. KW - TEMPORAL RESPONSE. KW - MESSENGER-RNA. KW - HUMAN FETAL. KW - CORD BLOOD. KW - HUMAN-MILK. KW - BIRTH. KW - 3123 Gynaecology and paediatrics. U2 - 10.1038/s41390-018-0054-4. DO - 10.1038/s41390-018-0054-4. M3 - Review Article. VL - 84. SP - 807. EP - 812. JO - Pediatric Research. JF - Pediatric Research. SN - 0031-3998. IS - 6. ER - ...
https://researchportal.helsinki.fi/fi/publications/robust-increases-in-erythropoietin-production-by-the-hypoxic-fetu-2
Effect of hemoglobin (Hb) maintenance of subcutaneous (SC) or intravenous (IV) C. E. R. A. (Continuous Erythropoietin Receptor...Effect of hemoglobin (Hb) maintenance of subcutaneous (SC) or intravenous (IV) C. E. R. A. (Continuous Erythropoietin Receptor...
TY - JOUR. T1 - Effect of hemoglobin (Hb) maintenance of subcutaneous (SC) or intravenous (IV) C. E. R. A. (Continuous Erythropoietin Receptor Activator) in chronic kidney disease (CKD) patients not on dialysis. AU - Yuzawa, Yukio. AU - Hotta, Osamu. AU - Suzuki, Hiromichi. AU - Oishi, Tetsuya. AU - Mochizuki, Takahiro. AU - Wakasa, Mikio. AU - Uda, Susumu. AU - Kanno, Yutaka. AU - Horikawa, Kazuhiro. AU - Hara, Soshun. AU - Ichida, Shizunori. AU - Morozumi, Kunio. AU - Shimizu, Hideaki. AU - Tsuyuki, Mikito. AU - Tamai, Hirofumi. AU - Asada, Hiroaki. AU - Naruse, Tomohiko. AU - Inaguma, Daijyo. AU - Suzuki, Satoshi. AU - Kasuga, Hirotake. AU - Ishimura, Eiji. AU - Imai, Enyu. AU - Yamauchi, Atsushi. AU - Saika, Yasushi. AU - Saito, Yoshihiko. AU - Taki, Masafumi. AU - Kawanishi, Hideki. AU - Minakuchi, Jun. AU - Yuasa, Kenji. AU - Miyake, Susumu. AU - Takeda, Kazuhito. AU - Yasunaga, Chikao. AU - Okuda, Seiya. AU - Nakamoto, Masahiko. AU - Saito, Takao. AU - Tsuruya, Kazuhiko. AU - Hirakata, ...
https://pure.fujita-hu.ac.jp/en/publications/effect-of-hemoglobin-hb-maintenance-of-subcutaneous-sc-or-intrave
Endogenous erythropoietin level and effects of exogenous erythropoietin in a rat model of blunt chest trauma-induced pulmonary...
METHODS: Thirty-five rats were divided into 3 groups. In the baseline control group (BC, n=7), rats were uninjured and untreated. In the positive control group (PC, n=21) rats were injured but untreated. In the EPO-24 group (n=7), rats were injured and a single dose of intra-peritoneal EPO (5000 IU/kg) was administered immediately after lung injury. The PC group was divided into 3 subgroups: PC-6 (n=7), PC-12 (n=7), and PC-24 (n=7). The BC group was subjected to thoracotomy, and the right lung was harvested. The PC subgroups were eu-thanized at 6, 12, and 24 hours after injury, respectively. The EPO-24 group was euthanized at the 24th hour after injury. Lung samples were obtained, levels of malondialdehyde (MDA) and EPO were analyzed, and activities of superoxide dismutase (SOD) and catalase (CAT) were then measured in homogenized lung tissue samples. Histologic damage to lung tissue in the BC group, the EPO-24 group, and PC subgroup euthanized at the 24th hour after injury were scored by a ...
http://www.tjtes.org/eng/jvi.aspx?pdir=travma&plng=eng&un=UTD-09483&look4=
Find Recombinant Human Erythropoietin Alfa / Epoetin Alfa (50mcg) alternatives online at lowest price in India - PillsBills.comFind Recombinant Human Erythropoietin Alfa / Epoetin Alfa (50mcg) alternatives online at lowest price in India - PillsBills.com
Search for Recombinant Human Erythropoietin Alfa / Epoetin Alfa (50mcg) Manufacturers / Generic Brands / Substitute / alternatives, prices, m.r.p. Order Medicines online on PillsBills.com. Free shipping all over India.
https://www.pillsbills.com/tags/recombinant-human-erythropoietin-alfa-epoetin-alfa-50mcg/
Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo<...
TY - JOUR. T1 - Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo. AU - Clibon, U.. AU - Bonewald, Lynda. AU - Caro, J.. AU - Roodman, G. David. PY - 1990. Y1 - 1990. N2 - Tumor necrosis factor-α (TNF) is a monokine produced by activated macrophages that has cytotoxic and cytostatic effects on erythroid progenitor cells. We have recently shown that Chinese hamster ovary cells transfected with the human TNF gene and which constitutively express TNF induced a hypoproliferative anemia, mild thrombocytopenia, and mild leukocytosis when injected into nude mice. We have used this murine model to determine if treatment with recombinant human erythropoietin can prevent or ameliorate the anemia seen with long-term continuous exposure to high concentrations of TNF. Mice bearing TNF-producing tumors became anemic with hematocrits ranging from 30 to 32%. Treatment with recombinant human erythropoietin (100-1000 U/kg body weight three times per ...
https://indiana.pure.elsevier.com/en/publications/erythropoietin-fails-to-reverse-the-anemia-in-mice-continuously-e
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer - Full Text View -...Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer - Full Text View -...
RATIONALE: Darbepoetin alfa and epoetin alfa may stimulate red blood cell production and treat anemia in patients who are receiving chemotherapy. It is not yet known whether darbepoetin alfa is more effective than epoetin alfa in treating patients with anemia.. PURPOSE: Randomized phase III trial to compare the effectiveness of darbepoetin alfa with that of epoetin alfa in treating anemia in patients who are receiving chemotherapy for cancer. ...
https://clinicaltrials.gov/show/NCT00070382
Regulation of expression of the erythropoietin gene. - NDM Research Building
Erythropoietin, a hormone produced in the adult kidney, controls erythrocyte production. In response to ischemic or hypoxic hypoxia, the level of expression of the gene increases markedly. We have a limited understanding of the factors governing the tissue specificity of erythropoietin gene expression but considerable progress has been made toward understanding the mechanisms that increase erythropoietin gene expression in response to hypoxia. An increase in transcription occurs, mediated (at least in part) by formation of a heterodimeric DNA binding complex termed hypoxia inducible factor 1. Transcriptional regulation mediated by this complex has now been shown to modulate the expression of a number of other genes in a wide range of cell types.
https://www.ndmrb.ox.ac.uk/research/research/publications/74074
Erythropoietin Market (EPO) with Focus on Asia - Industry Analysis with 2016-2020 Forecasts - Get NewsErythropoietin Market (EPO) with Focus on Asia - Industry Analysis with 2016-2020 Forecasts - Get News
Erythropoietin is a substance produced by the kidney that leads to the formation of red blood cells in the bone marrow. It is a glycoprotein hormone which regulates erythropoiesis (Red Blood Cell production). For erythrocyte precursors present in the bone marrow, EPO acts as a cytokine. Commonly referred to as hematopoietin or hemopoietin, erythropoietin is also known to have other biological functions, such as involvement in the wound healing cycle and brains response to neuronal injury. People suffering from End Stage Renal Disease (ESRD), HIV or undergoing chemotherapy are not able to produce enough EPO on their own and thus, are administered with synthetic or recombinant erythropoietin which has the similar sequence of amino acids. Recombinant erythropoietin is a kind of therapeutic agent devised using DNA technology.. Request a sample of this report at http://www.orbisresearch.com/contacts/request-sample/127811 .. On the bases of their molecular structure, EPO drugs can be divided into ...
http://www.getnews.info/579488/erythropoietin-market-epo-with-focus-on-asia-industry-analysis-with-20162020-forecasts.html
Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic...
TY - JOUR. T1 - Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. AU - van der Putten, K.. AU - Jie, K.E.. AU - van den Broek, D.. AU - Kraaijenhagen, R.J.. AU - Laarakkers, C.. AU - Swinkels, D.W.. AU - Braam, B.. AU - Gaillard, C.A.J.M.. PY - 2010. Y1 - 2010. U2 - 10.1093/eurjhf/hfq099. DO - 10.1093/eurjhf/hfq099. M3 - Article. C2 - 20601671. VL - 12. SP - 943. EP - 950. JO - European Journal of Heart Failure. JF - European Journal of Heart Failure. SN - 1388-9842. IS - 9. ER - ...
https://research.vumc.nl/en/publications/hepcidin-25-is-a-marker-of-the-response-rather-than-resistance-to
Phorbol ester inhibits erythropoietin production in human hepatoma cells (Hep G2). - Target Discovery Institute
Using the human hepatoma cell line Hep G2, we have studied a possible role of protein kinase C (PKC) activity for regulation of erythropoietin (EPO) production. During a 72-h incubation, EPO production by the cells was stimulated sevenfold by exposure to low oxygen tension (1%) and threefold by exposure to cobaltous chloride (100 microM). The phorbol ester phorbol 12-myristate-13 acetate (PMA) led to a concentration-dependent inhibition of basal and stimulated EPO formation (ED50 10 nM). This decrease of EPO production, which was apparent already after 1 h of incubation with PMA, reached its maximal effect after 24 h and held on for 72 h. It was paralleled by an inhibition of the increase of EPO mRNA levels in response to stimulation. A 24-h preincubation of the cells with PMA (100 nM) virtually blunted the effect of hypoxia on EPO formation. Recovery of EPO synthesis after removal of PMA took 48-72 h. The effect of PMA on EPO production was mimicked by phorbol 12,13-dibutyrate (ED50 1 microM) but not
https://www.tdi.ox.ac.uk/publications/74057
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies - Full Text View - ClinicalTrials.govChemotherapy Related Anemia in Patients With Non-Myeloid Malignancies - Full Text View - ClinicalTrials.gov
Chemotherapy can often cause anemia in patients with cancer. Anemia is a low number of red blood cells. The symptoms of anemia may include fatigue, dizziness, headache, chest pain, and shortness of breath. Erythropoietin is a hormone made by the kidneys that signals the bone marrow to produce more red blood cells. Recombinant human erythropoietin has been produced in the laboratory and has the same effect as the hormone produced by the body. Use of recombinant human erythropoietin allows the body to produce more red blood cells, possibly eliminating or decreasing your symptoms and the need for a red blood cell transfusion. Recombinant human erythropoietin is FDA approved to treat anemia in cancer patients receiving chemotherapy. This clinical study is investigating the effectiveness of darbepoetin alfa for the treatment of anemia in patients with non-myeloid malignancies who are receiving chemotherapy every three weeks. Darbepoetin alfa is a recombinant erythropoietic protein that stimulates the ...
https://clinicaltrials.gov/show/NCT00036023
Prevention of Anemia in Patients with Solid Tumors Receiving Platinum-Based Chemotherapy by Recombinant Human Erythropoietin ...Prevention of Anemia in Patients with Solid Tumors Receiving Platinum-Based Chemotherapy by Recombinant Human Erythropoietin ...
|i|Objectives:|/i| Platinum compounds are commonly associated with significant anemia. Erythropoietin administration has been found effective in correcting anemia in patients with solid tu
https://www.karger.com/Article/Abstract/67766
enQuireBio™ Recombinant Bovine Erythropoietin / EPO Protein 200μg enQuireBio™ Recombinant Bovine Erythropoietin / EPO Protein ...enQuireBio™ Recombinant Bovine Erythropoietin / EPO Protein 200μg enQuireBio™ Recombinant Bovine Erythropoietin / EPO Protein ...
Shop a large selection of Proteins A-Z products and learn more about enQuireBio™ Recombinant Bovine Erythropoietin / EPO Protein 200μg enQuireBio™ Recombinant
https://www.fishersci.se/shop/products/recombinant-bovine-erythropoietin-epo-protein-6/15939169
Cardioprotection by Recombinant Human Erythropoietin Following Acute Experimental Myocardial Infarction: Dose Response and...Cardioprotection by Recombinant Human Erythropoietin Following Acute Experimental Myocardial Infarction: Dose Response and...
Background: Recombinant human erythropoietin (rhEPO) protects tissue from ischemic damage, but translation of this finding into useful guidelines with respect to human trials for myocardial infarction
https://link.springer.com/article/10.1007%2Fs10557-005-3189-6
ErythropoietinErythropoietin
"Erythropoietin". Dictionary.com Unabridged (Online). n.d. "erythropoietin - definition of erythropoietin in English from the ... Erythropoietin production can be induced by HIF-2α as well as by PGC-1α. Erythropoietin also activates these factors, resulting ... Erythropoietin has been shown to exert its effects by binding to the erythropoietin receptor (EpoR). EPO binds to the ... Exogenous erythropoietin, recombinant human erythropoietin (rhEPO), is produced by recombinant DNA technology in cell culture ...
https://en.wikipedia.org/wiki/Erythropoietin
Erythropoietin receptorErythropoietin receptor
... has been shown to interact with: CRKL, Erythropoietin, Grb2, Janus kinase 2, LYN, PIK3R1, PTPN6, SOCS2 ... Zhu Y, D'Andrea AD (Mar 1994). "The molecular physiology of erythropoietin and the erythropoietin receptor". Current Opinion in ... "Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor". ... The erythropoietin receptor (EpoR) is a protein that in humans is encoded by the EPOR gene. EpoR is a 52kDa peptide with a ...
https://en.wikipedia.org/wiki/Erythropoietin_receptor
Erythropoietin in neuroprotectionErythropoietin in neuroprotection
Erythropoietin mutants R103-E and S100-E (though S100 in Epo doesn't exist) has been reported to be non-erythropoietin but ... Erythropoietin in neuroprotection is the use of the glycoprotein erythropoietin (Epo) for neuroprotection. Epo controls ... Campana WM, Myers RR (August 2001). "Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes ... "Erythropoietin and erythropoietin receptor in the developing human central nervous system". Pediatr. Res. 43 (1): 40-9. doi: ...
https://en.wikipedia.org/wiki/Erythropoietin_in_neuroprotection
Continuous erythropoietin receptor activatorContinuous erythropoietin receptor activator
... (CERA) is the generic term for drugs in a new class of third-generation ... Lasne, F; Martin, L; Martin, J. A; De Ceaurriz, J (2009). "Detection of continuous erythropoietin receptor activator in blood ... CERAs have an extended half-life and a mechanism of action that promotes increased stimulation of erythropoietin receptors ... "Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in ...
https://en.wikipedia.org/wiki/Continuous_erythropoietin_receptor_activator
EpileptogenesisEpileptogenesis
... the hormone erythropoietin; and, paradoxically, drugs such as the α2 adrenergic receptor antagonist atipamezole and the CB1 ...
https://en.wikipedia.org/wiki/Epileptogenesis
RejuvenationRejuvenation
... erythropoietin (EPO); 4. insulin; 5. DHEA; 6. melatonin; 7. thyroid; 8. pregnenolone. In theory, if all or some of these ...
https://en.wikipedia.org/wiki/Rejuvenation
Doping at the 1999 Tour de FranceDoping at the 1999 Tour de France
13 June 2006). "Detection of recombinant human erythropoietin in urine for doping analysis - Interpretation of isoelectric ... Françoise Lasne & Jacques de Ceaurriz (8 June 2000). "Recombinant erythropoietin in urine". Nature. 405 (6787): 635. Bibcode: ...
https://en.wikipedia.org/wiki/Doping_at_the_1999_Tour_de_France
Doping at the 1998 Tour de FranceDoping at the 1998 Tour de France
13 June 2006). "Detection of recombinant human erythropoietin in urine for doping analysis - Interpretation of isoelectric ... Françoise Lasne & Jacques de Ceaurriz (8 June 2000). "Recombinant erythropoietin in urine". Nature. 405 (6787): 635. Bibcode: ... erythropoietin (EPO), growth hormones, testosterone and amphetamines. When raiding the Festina headquarters in France, the ...
https://en.wikipedia.org/wiki/Doping_at_the_1998_Tour_de_France
List of stripped Olympic medalsList of stripped Olympic medals
Sytkowski, Arthur J. (May 2006). Erythropoietin: Blood, Brain and Beyond. John Wiley & Sons. pp. 187-. ISBN 978-3-527-60543-9. ...
https://en.wikipedia.org/wiki/List_of_stripped_Olympic_medals
ZidovudineZidovudine
Fisher, J. W. (1997). "Erythropoietin: physiologic and pharmacologic aspects". Proceedings of the Society for Experimental ... Fisher, J. W. (2003). "Erythropoietin: physiology and pharmacology update". Experimental Biology and Medicine. 228 (1): 1-14. ...
https://en.wikipedia.org/wiki/Zidovudine
EpitestosteroneEpitestosterone
Sytkowski, Arthur J. (May 2006). Erythropoietin: Blood, Brain and Beyond. John Wiley & Sons. pp. 187-. ISBN 978-3-527-60543-9. ...
https://en.wikipedia.org/wiki/Epitestosterone
Tan Chorh ChuanTan Chorh Chuan
Tan completed his PhD in 1992 with a dissertation entitled "Regulation of erythropoietin messenger RNA". Upon graduation in ... Tan, Chorh Chuan (1992). Regulation of Erythropoietin Messenger RNA. National University of Singapore. Archived from the ...
https://en.wikipedia.org/wiki/Tan_Chorh_Chuan
List of Olympic Games scandals and controversiesList of Olympic Games scandals and controversies
Sytkowski, Arthur J. (May 2006). Erythropoietin: Blood, Brain and Beyond. John Wiley & Sons. p. 187. ISBN 978-3-527-60543-9. " ...
https://en.wikipedia.org/wiki/List_of_Olympic_Games_scandals_and_controversies
Soviet UnionSoviet Union
Sytkowski, Arthur J. (May 2006). Erythropoietin: Blood, Brain and Beyond. John Wiley & Sons. pp. 187-. ISBN 978-3-527-60543-9. ...
https://en.wikipedia.org/wiki/Soviet_Union
1980 Summer Olympics1980 Summer Olympics
Sytkowski, Arthur J. (May 2006). Erythropoietin: Blood, Brain and Beyond. John Wiley & Sons. pp. 187-. ISBN 978-3-527-60543-9. ...
https://en.wikipedia.org/wiki/1980_Summer_Olympics
Doping in sportDoping in sport
Erythropoietin (EPO) is largely taken by endurance athletes who seek a higher level of red blood cells, which leads to more ... The Juventus team has been accused of using erythropoietin (EPO) and the matter went to trial in 2004. In November 2004, club ... Sytkowski, Arthur J. (May 2006). Erythropoietin: Blood, Brain and Beyond. John Wiley & Sons. pp. 187-. ISBN 978-3-527-60543-9. ... that the purchase of erythropoietin or its administration to the athletes of the club does not emerge from any act of the trial ...
https://en.wikipedia.org/wiki/Doping_in_sport
PolycythemiaPolycythemia
In many families, PFCP is due to an autosomal dominant mutation in the EPOR erythropoietin receptor gene. PFCP can cause an ... The production of red blood cells (or erythropoeisis) in the body is regulated by erythropoietin, which is a protein produced ... Ebert BL, Bunn HF (September 1999). "Regulation of the erythropoietin gene". Blood. 94 (6): 1864-1877. doi:10.1182/blood.V94.6. ... Secondary polycythemia is caused by either natural or artificial increases in the production of erythropoietin, hence an ...
https://en.wikipedia.org/wiki/Polycythemia
Endocrine glandEndocrine gland
... erythropoietin and renin); the thymus; skin (cholecalciferol); and adipose tissue (leptin and resistin). Endocrine glands ...
https://en.wikipedia.org/wiki/Endocrine_gland
Doping at the Olympic GamesDoping at the Olympic Games
Sytkowski, Arthur J. (May 2006). Erythropoietin: Blood, Brain and Beyond. John Wiley & Sons. pp. 187-. ISBN 978-3-527-60543-9. ...
https://en.wikipedia.org/wiki/Doping_at_the_Olympic_Games
AltitudeAltitude
Ismailov, RM (July-September 2013). "Erythropoietin and epidemiology of Alzheimer disease". Alzheimer Dis. Assoc. Disord. 27 (3 ... the recent hypothesis suggests that high altitude could be protective against Alzheimer's disease via action of erythropoietin ...
https://en.wikipedia.org/wiki/Altitude
MegakaryocyteMegakaryocyte
It has high homology with erythropoietin. It is essential for the formation of an adequate quantity of platelets. After budding ... Certain cytokines such as IL-3, IL-6, IL-11, LIF, erythropoietin, and thrombopoietin all stimulate the maturation of ... Jelkmann W (2001). "The role of the liver in the production of thrombopoietin compared with erythropoietin". Eur. J. ... and erythropoietin. The megakaryocyte develops through the following lineage: CFU-Me (pluripotential hemopoietic stem cell or ...
https://en.wikipedia.org/wiki/Megakaryocyte
Renal cell carcinomaRenal cell carcinoma
... due to increased erythropoietin secretion; varicocele, which is seen in males as an enlargement of the pampiniform plexus of ... anaemia resulting from depression of erythropoietin; erythrocytosis (increased production of red blood cells) ...
https://en.wikipedia.org/wiki/Renal_cell_carcinoma
Hereditary haemochromatosisHereditary haemochromatosis
"The interaction of iron and erythropoietin". sickle.bwh.harvard.edu. Ofojekwu, Mary-Jane N.; Nnanna, Ogbonnaya U.; Okolie, ...
https://en.wikipedia.org/wiki/Hereditary_haemochromatosis
UFC 174UFC 174
Ali Bagautinov tested positive for erythropoietin. The following fighters were awarded $50,000 bonuses: Fight of the Night: Tae ... announced that Bagautinov tested positive for erythropoietin (EPO) prior to the title fight. In response, the BCAC has ...
https://en.wikipedia.org/wiki/UFC_174
UFC Fight Night: Cejudo vs. DillashawUFC Fight Night: Cejudo vs. Dillashaw
Dillashaw tested positive for erythropoietin (EPO). The following fighters were awarded $50,000 bonuses: Fight of the Night: ... as it was revealed he tested positive to erythropoietin in a fight night test. martial arts portal New York City portal New ...
https://en.wikipedia.org/wiki/UFC_Fight_Night:_Cejudo_vs._Dillashaw
List of recombinant proteinsList of recombinant proteins
Erythropoietin (EPO): Epogen from Amgen Granulocyte colony-stimulating factor (G-CSF): filgrastim sold as Neupogen from Amgen; ... Inoue N, Takeuchi M, Ohashi H, Suzuki T (1995). "The production of recombinant human erythropoietin". Biotechnology Annual ...
https://en.wikipedia.org/wiki/List_of_recombinant_proteins
Assessment of kidney functionAssessment of kidney function
... such as erythropoietin; and activation of vitamin D.[citation needed] Much of renal physiology is studied at the level of the ... such as erythropoietin; and activation of vitamin D.[citation needed] The functions of the kidney include maintenance of acid- ...
https://en.wikipedia.org/wiki/Assessment_of_kidney_function
MepitiostaneMepitiostane
175-. ISBN 978-94-011-4439-1. "Mepitiostane". Allan J. Erslev (1991). Erythropoietin: molecular, cellular, and clinical biology ...
https://en.wikipedia.org/wiki/Mepitiostane
Fu-Kuen LinFu-Kuen Lin
Lin is the inventor of seven US patents covering "DNA Sequences Encoding Erythropoietin" and "Production of Erythropoietin". ... In 1983 his team successfully established the gene coding for it and recombinant human erythropoietin was approved by the US ... He was involved with Amgen's recombinant human erythropoietin (EPO) project from the start, and was soon leading the team, ... Lin F. (1984), DNA sequences encoding erythropoietin., US-Patent 4,703,008 (30 November 1984). Lin F. et al. (1985) "Cloning ...
https://en.wikipedia.org/wiki/Fu-Kuen_Lin
Constance Tom NoguchiConstance Tom Noguchi
In 1991, Noguchi isolated and cloned the human erythropoietin receptor gene.Erythropoietin is an essential hormone for red ... Erythropoietin regulation is involved in metabolism in a number of ways, including oxygen delivery, maintenance of white ... Noguchi, CT; Bae, KS; Chin, K; Wada, Y; Schechter, AN; Hankins, WD (15 November 1991). "Cloning of the human erythropoietin ... Suresh, Sukanya; Rajvanshi, Praveen Kumar; Noguchi, Constance T. (2020). "The Many Facets of Erythropoietin Physiologic and ...
https://en.wikipedia.org/wiki/Constance_Tom_Noguchi
Erythropoietin test: MedlinePlus Medical EncyclopediaErythropoietin test: MedlinePlus Medical Encyclopedia
The erythropoietin test measures the amount of a hormone called erythropoietin (EPO) in blood. ... The erythropoietin test measures the amount of a hormone called erythropoietin (EPO) in blood. ...
https://medlineplus.gov/ency/article/003683.htm
Polycythemia and Erythropoietin in a Patient With Chronic Kidney DiseasePolycythemia and Erythropoietin in a Patient With Chronic Kidney Disease
Hydronephrotic kidney disease can sometimes result in erythropoietin-associated secondary polycythemia, even in non-functioning ... At presentation, he had a hemoglobin level of 220 g/l, a serum erythropoietin level of 27.4 U/l and a serum creatinine level of ... Polycythemia and Increased Erythropoietin in a Patient With Chronic Kidney Disease. Simone Stark; Björn Winkelmann; Christof ... Cite this: Polycythemia and Increased Erythropoietin in a Patient With Chronic Kidney Disease - Medscape - Apr 01, 2007. ...
https://www.medscape.com/viewarticle/555373
Erythropoietin testErythropoietin test
The erythropoietin test measures the amount of a hormone called erythropoietin (EPO) in blood. EPO is made by cells in the ... The erythropoietin test measures the amount of a hormone called erythropoietin (EPO) in blood. ...
https://www.ucsfhealth.org/medical-tests/erythropoietin-test
Erythropoietin abuse in athletesErythropoietin abuse in athletes
... Nature. 1996 Mar 14;380(6570):113. doi: 10.1038/380113a0. ...
https://pubmed.ncbi.nlm.nih.gov/8600382/?dopt=Abstract
Browsing by Subject ErythropoietinBrowsing by Subject "Erythropoietin"
Proposed 1st WHO Erythropoietin antibody reference panel: Expert Committee on Biological Standardization: Geneva, 12 to 16 ... WHO international collaborative study of the proposed 3rd international standard for erythropoietin, recombinant, for bioassay ...
https://extranet.who.int/iris/restricted/browse?authority=Erythropoietin&type=mesh
Recombinant Human Erythropoietin in Cancer-Related AnemiaRecombinant Human Erythropoietin in Cancer-Related Anemia
Based on these trials, recombinant erythropoietin was approved for the treatment of anemia in patients with nonmyeloid ... The clinical development of recombinant human erythropoietin (rHuEPO) has had a remarkable impact on the clinical practice of ... Erythropoietin Therapy in Cancer Chemotherapy Patients. Pathophysiology. Studies of recombinant erythropoietin demonstrated ... The Glaspy et al study utilized a dose of erythropoietin at 150 U/kg SC three times weekly with an increase to 300 U/kg SC ...
https://www.cancernetwork.com/view/recombinant-human-erythropoietin-cancer-related-anemia
Erythropoietin (EPO) ELISA Kit | STEMCELL TechnologiesErythropoietin (EPO) ELISA Kit | STEMCELL Technologies
A specific in vitro bioassay for measuring erythropoietin levels in human serum and plasma. Wognum AW et al. Blood 1990 OCT ... Immunochemical analysis of monoclonal antibodies to human erythropoietin. Wognum AW et al. Experimental hematology 1990 MAR ... Anaemia due to malignant disease responds to erythropoietin therapy in many cases; failure to respond is a poor prognostic sign ... The accurate measurement of biologically active erythropoietin (Ep) in human serum and plasma using present in vivo and in ...
https://www.stemcell.com/products/product-types/elisas/erythropoietin-epo-elisa-kit.html
Feline erythropoietin receptor agonists - Patent US-10287336-B2 - PubChemFeline erythropoietin receptor agonists - Patent US-10287336-B2 - PubChem
US-10287336-B2 chemical patent summary.
https://pubchem.ncbi.nlm.nih.gov/patent/US-10287336-B2
Hospira, Inc. Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients | BioSpaceHospira, Inc. Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients | BioSpace
Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients - read this article along with other careers ... Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients. Published: Jul 26, 2010 ... Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy. ... Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an ...
https://www.biospace.com/article/hospira-inc-begins-phase-i-u-s-clinical-trial-of-biosimilar-erythropoietin-in-renal-patients-/
Rat Erythropoietin, EPO ELISA Kit | CSB-E07323r | CusabioRat Erythropoietin, EPO ELISA Kit | CSB-E07323r | Cusabio
Rat Erythropoietin, EPO ELISA Kit from Cusabio. Cat#: CSB-E07323r. US, UK & Europe Distribution. Online Order or Request ... Rat Erythropoietin, EPO ELISA Kit , CSB-E07323r Cusabio Elisa Rat Erythropoietin, EPO ELISA Kit , CSB-E07323r. (No reviews yet ... Pig Erythropoietin, EPO ELISA Kit , CSB-E12056p , CusabioPig Erythropoietin, EPO ELISA Kit is Available at Gentaur Genprice ... Dog Erythropoietin, EPO ELISA Kit , CSB-E11303c , CusabioDog Erythropoietin, EPO ELISA Kit is Available at Gentaur Genprice ...
https://joplink.net/rat-erythropoietin-epo-elisa-kit-csb-e07323r/
Erythropoietin and Diabetic Retinopathy | Abstract
Erythropoietin and Diabetic Retinopathy. Francesco Semeraro, Eliana Forbice, Francesco Morescalchi, Simone Donati, Claudio ...
https://www.iomcworld.com/abstract/erythropoietin-and-diabetic-retinopathy-26997.html
LEGEND MAX Human Erythropoietin EPO ELISA Kit with Pre-coated PlatesLEGEND MAX Human Erythropoietin EPO ELISA Kit with Pre-coated Plates
Erythropoietin (EPO) is the most important hormone regulating erythropoiesis. ... Human Erythropoietin (EPO) ELISA Kit with Pre-coated Plates - ... Erythropoietin (EPO) is the most important hormone regulating ...
https://www.biolegend.com/de-de/products/legend-max-human-erythropoietin-epo-elisa-kit-with-pre-coated-plates-10734
Assessment of Patient Perceptions about Use of Wepox PenTM (Recombinant Erythropoietin Delivery Device with 30,000 IU Cartridge...Assessment of Patient Perceptions about Use of Wepox PenTM (Recombinant Erythropoietin Delivery Device with 30,000 IU Cartridge...
... loaded with 30,000 IU cartridge of recombinant erythropoietin) in the management of anemia in adult chronic kidney disease (CKD ... adult CKD patients treated with erythropoietin were enrolled from November 2015 to December 2016 to understand their opinions ... Moreover, confidence of patient is high while using erythropoietin with this device. Self-administration of erythropoietin with ... Recombinant human erythropoietin, the choice of therapy for anemia in CKD patients can be administered by subcutaneous and ...
https://www.scirp.org/journal/paperinformation.aspx?paperid=77137
Peripheral neuropathy response to erythropoietin in type 2 diabetic patients with mild to moderate renal failure | Semantic...Peripheral neuropathy response to erythropoietin in type 2 diabetic patients with mild to moderate renal failure | Semantic...
Peripheral neuropathy response to erythropoietin in type 2 diabetic patients with mild to moderate renal failure by Mahshid S ... Anemia with erythropoietin deficiency occurs early in diabetic nephropathy.. *D. Bosman, A. Winkler, J. Marsden, I. Macdougall ... Effect of erythropoietin therapy on polyneuropathy in predialytic patients.. *K. Hassan, W. Simri, +4 authors. B. Kristal ... Age-associated changes in vascular health and its relation with erythropoietin. *Jyoti P Khodnapur, Kusal K. Das ...
https://www.semanticscholar.org/paper/Peripheral-neuropathy-response-to-erythropoietin-in-Hosseini-Zare-Dashti-Khavidaki/aae49190f016fb439212ae92eb9ed651362ab4f8
David Weatherall - Scientist - Age-dependent erythropoietin response and work in Papua New Guinea - Web of StoriesDavid Weatherall - Scientist - Age-dependent erythropoietin response and work in Papua New Guinea - Web of Stories
David Weatherall talks about Age-dependent erythropoietin response and work in Papua New Guinea ... that age and haemoglobin are independent variables for erythropoietin response. And then if you start to draw erythropoietin ... Age-dependent erythropoietin response and work in Papua New Guinea 44 03:21 ... So if youve got five grams of haemoglobin at the age of two years, on average your erythropoietin response will be much higher ...
https://www.webofstories.com/play/david.weatherall/23
Secondary erythrocytosis associated with high plasma erythropoietin concentrations in a dog with cecal leiomyosarcoma in:...Secondary erythrocytosis associated with high plasma erythropoietin concentrations in a dog with cecal leiomyosarcoma in:...
Secondary erythrocytosis associated with high plasma erythropoietin concentrations in a dog with cecal leiomyosarcoma ... Secondary erythrocytosis associated with high plasma erythropoietin concentrations in a dog with cecal leiomyosarcoma ...
https://avmajournals.avma.org/abstract/journals/javma/220/4/javma.2002.220.486.xml
GMS | 78. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V. | Effect...
Conclusion: Erythropoietin has only a minor protective effect on survival of SGC. However, EPO led to an increased neutrite ... It has been recently demonstrated that erythropoietin (EPO) attenuates apoptosis of ganglion cells. The aim of the present ...
https://www.egms.de/static/de/meetings/hno2007/07hno031.shtml
Erythropoietin | Johns Hopkins HIV GuideErythropoietin | Johns Hopkins HIV Guide
Erythropoietin answers are found in the Johns Hopkins HIV Guide powered by Unbound Medicine. Available for iPhone, iPad, ... "Erythropoietin." Johns Hopkins HIV Guide, 2016. Johns Hopkins Guide, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide ... Erythropoietin is a topic covered in the Johns Hopkins HIV Guide. To view the entire topic, please log in or purchase a ... TY - ELEC T1 - Erythropoietin ID - 545068 A1 - Smith,Janessa,Pharm.D., BCPS AU - Pham,Paul,Pharm.D. Y1 - 2016/10/04/ BT - Johns ...
https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545068/all/Erythropoietin?q=Amphotericin+B
G-protein α subunit Giα2 mediates erythropoietin signal transduction in human erythroid precursors<...
N2 - Erythropoietin induces a dose-dependent increase in cytosolic calcium in human erythroblasts that is mediated by a voltage ... AB - Erythropoietin induces a dose-dependent increase in cytosolic calcium in human erythroblasts that is mediated by a voltage ... Erythropoietin induces a dose-dependent increase in cytosolic calcium in human erythroblasts that is mediated by a voltage- ... abstract = "Erythropoietin induces a dose-dependent increase in cytosolic calcium in human erythroblasts that is mediated by a ...
https://pennstate.pure.elsevier.com/en/publications/g-protein-%CE%B1-subunit-gi%CE%B12-mediates-erythropoietin-signal-transduct
Evolution of the receptors for growth hormone, prolactin, erythropoietin and thrombopoietin in relation to the vertebrate...Evolution of the receptors for growth hormone, prolactin, erythropoietin and thrombopoietin in relation to the vertebrate...
... erythropoietin and thrombopoietin in relation to the vertebrate tetraploidizations ... Evolution of the receptors for growth hormone, prolactin, erythropoietin and thrombopoietin. .pdf (. 9.55 MB. ). view. download ... Cite this article as: Ocampo Daza D, Larhammar D. Evolution of the receptors for growth hormone, prolactin, erythropoietin and ... Evolution of the receptors for growth hormone, prolactin, erythropoietin and thrombopoietin in relation to the vertebrate ...
https://figshare.com/articles/dataset/Evolution_of_the_receptors_for_growth_hormone_prolactin_erythropoietin_and_thrombopoietin_in_relation_to_the_vertebrate_tetraploidizations/5151157
Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. | Scholars@DukeHuman recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. | [email protected]
Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. ... Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Journal Article (Journal Article) ... Exogenous recombinant erythropoietin (rEpo) has been recently shown to increase tumour oxygenation in a mammary carcinoma model ...
https://scholars.duke.edu/display/pub732038
PREOPERATIVE USE OF ERYTHROPOIETIN IN ADOLESCENTS UNDERGOING SCOLIOSIS SURGERY | Anesthesiology | American Society of...PREOPERATIVE USE OF ERYTHROPOIETIN IN ADOLESCENTS UNDERGOING SCOLIOSIS SURGERY | Anesthesiology | American Society of...
PREOPERATIVE USE OF ERYTHROPOIETIN IN ADOLESCENTS UNDERGOING SCOLIOSIS SURGERY: HEMATOLOGIC, CARDIOVASCULAR AND SIDE EFFECTS P ... Preoperative Use of Erythropoietin in an Adolescent Jehovahs Witness Anesthesiology (September 1990) ... P Rothstein, D Roye, L Verdisco; PREOPERATIVE USE OF ERYTHROPOIETIN IN ADOLESCENTS UNDERGOING SCOLIOSIS SURGERY: HEMATOLOGIC, ... Effect of Single Recombinant Human Erythropoietin Injection on Transfusion Requirements in Preoperatively Anemic Patients ...
https://pubs.asahq.org/anesthesiology/article/75/3/A959/50451/PREOPERATIVE-USE-OF-ERYTHROPOIETIN-IN-ADOLESCENTS
The Metabolic Effect of Chronic Elevated Erythropoietin in Tg6 Mice | Diabetes | American Diabetes AssociationThe Metabolic Effect of Chronic Elevated Erythropoietin in Tg6 Mice | Diabetes | American Diabetes Association
Erythropoietin (EPO) is the cytokine required for erythrocyte production. However, EPO receptor (EpoR) expression is not ... The Metabolic Effect of Chronic Elevated Erythropoietin in Tg6 Mice HEATHER ROGERS; HEATHER ROGERS ... Erythropoietin (EPO) is the cytokine required for erythrocyte production. However, EPO receptor (EpoR) expression is not ... HEATHER ROGERS, OKSANA GAVRILOVA, CONSTANCE T. NOGUCHI; The Metabolic Effect of Chronic Elevated Erythropoietin in Tg6 Mice. ...
https://diabetesjournals.org/diabetes/article/67/Supplement_1/2035-P/55080/The-Metabolic-Effect-of-Chronic-Elevated
Erythropoietin (EPO)Erythropoietin (EPO)
Erythropoietin is a glycoprotein (about 30, 400 Daltons) that is produced primarily by the kidney and maintains red blood cell ...
https://www.southtees.nhs.uk/services/pathology/tests/erythropoietin-epo/
Bidirectional signalling between EphA2 and ephrinA1 increases tubular cell attachment, laminin secretion and modulates...Bidirectional signalling between EphA2 and ephrinA1 increases tubular cell attachment, laminin secretion and modulates...
... laminin secretion and modulates erythropoietin expression after renal hypoxic injury. Pflügers Archiv : European Journal of ... laminin secretion and modulates erythropoietin expression after renal hypoxic injury. Item availability may be restricted. ... laminin secretion and modulates erythropoietin expression after renal hypoxic injury ...
https://www.zora.uzh.ch/id/eprint/124667/
KAKEN - Research Projects | Studies on renal O 2 sensing mechanism- with special relevance to erythropoietin production. ...KAKEN - Research Projects | Studies on renal O 2 sensing mechanism- with special relevance to erythropoietin production. ...
Publications] Shimizu,S.,Sakata,S.,Enoki,Y.,Ohga,Y.,Oki,I.& Kohzuki,H.: Temporal changes of plasma erythropoietin level in ... Publications] Shimizu,S.,Sakata,S.,Enoki,Y.,Ohga,Y.,Oki,I.& Kohzuki,H.: Temporal changes of plasma erythropoietin level in ... Publications] Sakata,S.et al.: Plasma erythropoietin in mice at simulated high-altitude. High-altitude Medicine (Ueda,G.,ed ... Publications] Sakata,S.et al.: Improved microbioassay for plasma erythropoietin based on CFU-E colony formation. Annals of ...
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-01570048/
The Effect of Systemic Erythropoietin and Oral prednisolone on Recent-Onset Non-Arteritic Anterior Ischemic Optic Neuropathy: A...The Effect of Systemic Erythropoietin and Oral prednisolone on Recent-Onset Non-Arteritic Anterior Ischemic Optic Neuropathy: A...
Thirty-four patients were randomized into group 1 (systemic erythropoietin), group 2 (oral steroids), and group 3 (control). ... Group A received 10,000 units of erythropoietin twice a day for three days. Group B received oral prednisone 75 mg daily for ... The findings of our study indicate the beneficial effects of systemic erythropoietin in preserving the function and structure ... To evaluate the effect of systemic erythropoietin, as well as oral steroids, in the management of recent onset non-arteritic ...
https://www.preprints.org/manuscript/201908.0081/v1
erythropoietinerythropoietin
Tag: erythropoietin. Australian racing embroiled in US doping saga. Mar 15, 2020. Tuesdays Horse3 Comments ... Posted in Horse RacingTagged the devil, arrests, ashley lebowitz, australia, cats fun, dexamethasone, EPO, erythropoietin, ... Posted in Horse RacingTagged blood doping horses, darbepoetin, erythropoietin, horses kentucky, james arledge, jan johnson, joe ... request determined in December that the four horses were negative for the performance-enhancing drugs erythropoietin or ...
https://tuesdayshorse.wordpress.com/tag/erythropoietin/
Stepping up versus standard doses of erythropoietin in preterm infants: a randomized controlled trial | Archive ouverte UNIGE Stepping up versus standard doses of erythropoietin in preterm infants: a randomized controlled trial | Archive ouverte UNIGE
In this study, it is hypothesized that a planned increase in the dose of recombinant human erythropoietin (rh-EPO) can prevent ... GUMY PAUSE, Fabienne et al. Stepping up versus standard doses of erythropoietin in preterm infants: a randomized controlled ... Birth Weight - Blood Transfusion/adverse effects - Dose-Response Relationship, Drug - Double-Blind Method - Erythropoietin/ ... Stepping up versus standard doses of erythropoietin in preterm infants: a randomized controlled trial. ...
https://archive-ouverte.unige.ch/unige:46642
Erythropoietin in tumor angiogenesisErythropoietin in tumor angiogenesis
... Annese, Tiziana;Tamma, Roberto;Ruggieri, Simona;Ribatti, Domenico 2019-01-01. Abstract. ... Erythropoietin (EPO) is a moonlighting protein since is ability to work as hormone, cytokine and growth factor. Its cardinal ... Erythropoietin (EPO) is a moonlighting protein since is ability to work as hormone, cytokine and growth factor. Its cardinal ...
https://ricerca.uniba.it/handle/11586/227918
Recombinant erythropoietinRenalELISA KitTransfusion requirementsReceptorsAnemiaSerumStimulatesDiabetic RetinopathyErythropoiesisRole of erythropoietinAmount of erythropoietinHypoxiaKidneyDialysis patientsPlasma erythropoietinRelease erythropoietinBiosimilar erythropoietinPolymorphismsHormonePreterm infantsInjectionHumanPatientsBiologicRs1617640TherapyGeneDarbepoetinApoptosisOxygen2016AntibodyBone2020EffectAssayResponseCellsAnemicLevelsIndiaBloodProductsSurvival
Recombinant erythropoietin12
  • Based on these trials, recombinant erythropoietin was approved for the treatment of anemia in patients with nonmyeloid malignancies in whom the anemia was caused by the effect of chemotherapy. (cancernetwork.com)
  • Subsequently, three large open-label, prospective trials of recombinant erythropoietin were performed in the community setting in anemic cancer chemotherapy patients. (cancernetwork.com)
  • For anemia due to other causes, it was assumedthat recombinant erythropoietin would not be effective, because it was assumedthat endogenous erythropoietin responses would occur. (cancernetwork.com)
  • Studies of recombinant erythropoietin demonstrated that theanemia experienced by the cancer chemotherapy patient is multifactorial partiallyattributable to the bone marrow suppression of the cancer chemotherapy, partlyrelated to the blunted erythropoietin response and to the suppressive effects ofcancer and cytokines on erythropoiesis. (cancernetwork.com)
  • Objective: To assess perceptions about ease of use and other benefits of Wepox Pen TM (loaded with 30,000 IU cartridge of recombinant erythropoietin) in the management of anemia in adult chronic kidney disease (CKD) patients. (scirp.org)
  • Conclusion: Wepox Pen TM (recombinant erythropoietin) is easy to use and does not cause significant pain or discomfort. (scirp.org)
  • Ability to self-administer recombinant erythropoietin with Wepox Pen TM is a great advantage which can make a significant difference for both CKD patients and doctors. (scirp.org)
  • Wepox Pen TM is a device loaded with 30,000 IU cartridge of recombinant erythropoietin available in Indian market for the treatment of anemia in CKD patients. (scirp.org)
  • Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. (duke.edu)
  • Exogenous recombinant erythropoietin (rEpo) has been recently shown to increase tumour oxygenation in a mammary carcinoma model. (duke.edu)
  • Matrices listed below were spiked with certain level of recombinant Erythropoietin (EPO) and the recovery rates were calculated by comparing the measured value to the expected amount of Erythropoietin (EPO) in samples. (uscnk.com)
  • With the advent of the administration of recombinant erythropoietin as a biologic therapy to increase red blood cell mass, an erythropoietin assay may be used also to aid in the prediction and monitoring of response to recombinant erythropoietin treatment of anemia. (yourlifelabs.com)
Renal15
  • Chronic renal insufficiency caused by obstructive hydronephrosis and accompanied by increased erythropoietin levels of renal origin and polycythemia. (medscape.com)
  • 1] In patients with chronic renal failureand low levels of endogenous erythropoietin, replacement therapy withrecombinant human erythropoietin (rHuEPO [Epogen, Procrit]) resulted innormalization of hemoglobin levels. (cancernetwork.com)
  • 2] Despite the significant impacterythropoietin therapy had on the renal dialysis patient population, this wasfelt to be a unique situation related to the lack of erythropoietin productionin the setting of renal failure. (cancernetwork.com)
  • Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy. (biospace.com)
  • Recombinant Human Erythropoietin Restrains Oxidative Stress in Streptozotocin-induced Diabetic Rats Exposed to Renal Ischemia Reperfusion Injury. (semanticscholar.org)
  • Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure. (semanticscholar.org)
  • Studies on renal O_2 sensing mechanism- with special relevance to erythropoietin production. (nii.ac.jp)
  • Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. (qxmd.com)
  • Erythropoietin is secreted by fibroblasts in the renal cortex. (medscape.com)
  • When a medical professional has reason to believe that renal dysfunction could be connected to a decline in erythropoietin production in a patient with chronic kidney disease, erythropoietin levels may be requested. (ultalabtests.com)
  • The test may be prescribed in cases of chronic renal disease to determine whether the kidneys are still capable of producing enough erythropoietin. (ultalabtests.com)
  • Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell Carcinoma. (edu.pl)
  • nevertheless, it has been published that functional erythropoietin receptor is not detected in endothelial, cardiac, neuronal, and renal cells. (biolegend.com)
  • 2010). Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure . (up.pt)
  • Relation between renal dysfunction requiring renal replacement therapy and promoter polymorphism of the erythropoietin gene in cardiac surgery. (cdc.gov)
ELISA Kit3
  • Rat Erythropoietin, EPO ELISA Kit is Available at Gentaur Genprice with the fastest delivery. (joplink.net)
  • CusabioMouse Erythropoietin, EPO ELISA Kit is Available at Gentaur Genprice with the fastest delivery.Online Order Payment is possible or send. (joplink.net)
  • CusabioHuman Erythropoietin, EPO ELISA Kit is Available at Gentaur Genprice with the fastest delivery.Online Order Payment is possible or send. (joplink.net)
Transfusion requirements2
  • A European randomized, placebo-controlled trial confirmed these QOL results, and a meta-analysis of other randomized clinical trials firmly supports the role of erythropoietin therapy in improving hemoglobin levels and reducing transfusion requirements. (cancernetwork.com)
  • Erythropoietin (EPO) has been used to try to reduce transfusion requirements, with variable outcomes. (medscape.com)
Receptors3
  • Cite this article as: Ocampo Daza D, Larhammar D. Evolution of the receptors for growth hormone, prolactin, erythropoietin and thrombopoietin in relation to the vertebrate tetraploidizations, General and Comparative Endocrinology 257 (2018) 143-160. (figshare.com)
  • Background: Accumulating evidences during the past decade suggest that erythropoietin (EPO) may have many beneficial actions other than on erythropoiesis because many non-hematopoietic cells, including kidney cells, also express EPO receptors. (who.int)
  • Erythropoietin receptors on cancer cells: a still open question. (edu.pl)
Anemia10
  • Based on this aggregate of data, the use of erythropoietin in the treatment of mild-to-moderate anemia has become a standard of care. (cancernetwork.com)
  • Although it was expected that higherdoses of erythropoietin would be required, it was remarkable that anemia wasameliorated in most patients with erythropoietin alone, despite this complexmultifaceted pathophysiology. (cancernetwork.com)
  • Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. (semanticscholar.org)
  • Anemia secondary to AZT and low erythropoietin levels in HIV+ pts. (hopkinsguides.com)
  • In some conditions, erythropoietin testing can be used in the assessment and differentiation of anemia, especially in patients receiving erythropoietin replacement therapy with an inadequate response. (medscape.com)
  • The Erythropoietin test measures levels of the hormone erythropoietin in your blood's serum and is generally used to identify the cause of anemia. (ultalabtests.com)
  • When a person develops anemia that does not seem to be due to iron deficiency, vitamin B12 or folate deficiency, shortened red blood cell lifespan, or heavy bleeding, a test for erythropoietin may be prescribed. (ultalabtests.com)
  • The main purpose of an erythropoietin test is to identify the root of anemia. (ultalabtests.com)
  • To assist identify whether low EPO may be contributing to or escalating the anemia, erythropoietin testing is prescribed. (ultalabtests.com)
  • Of interest, the study also reported 50 percent of the population received a reduced dose of erythropoietin, which most dialysis patients receive to combat anemia. (computermvp.com)
Serum1
  • At presentation, he had a hemoglobin level of 220 g/l, a serum erythropoietin level of 27.4 U/l and a serum creatinine level of 200.7 µmol/l (2.27 mg/dl). (medscape.com)
Stimulates3
  • Erythropoietin is a glycoprotein hormone that stimulates stem cells of the bone marrow for the production of red blood cells. (bccresearch.com)
  • These cells possess specific regulatory mechanisms, called hypoxia-inducible factors (HIFs), which, under hypoxic conditions, stimulate the production of erythropoietin, which stimulates the production of erythrocytes. (medscape.com)
  • Erythropoietin stimulates the bone marrow to produce more red blood cells which in turn increases the oxygen-carrying capacity of the blood. (fastescrowrefills.net)
Diabetic Retinopathy5
  • Objective: To determine whether sequence variation in the erythropoietin gene (EPO) is associated with the development of diabetic retinopathy (DR). Methods: This was a multicenter study based on 518 subjects with long-standing diabetes mellitus (DM), 173 with type 1DM(T1DM) and 345 with type 2DM(T2DM). (edu.au)
  • In this case-control study , the erythropoietin (EPO) promoter variant s1617640, linked to high intravitreal EPO concentrations and increased risk of diabetic retinopathy , was not associated with severe retinopathy of prematurity . (bvsalud.org)
  • Association of Erythropoietin Gene Polymorphisms With Type 2 Diabetic Retinopathy in Adult Patients From Northern India. (cdc.gov)
  • The GG genotype of erythropoietin rs1617640 polymorphism affects the risk of proliferative diabetic retinopathy in Slovenian subjects with type 2 diabetes mellitus: enemy or ally? (cdc.gov)
  • Association of polymorphisms in the erythropoietin gene with diabetic retinopathy: a case-control study and systematic review with meta-analysis. (cdc.gov)
Erythropoiesis1
  • Erythropoietin (EPO) is the most important hormone regulating erythropoiesis. (biolegend.com)
Role of erythropoietin1
  • The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. (medscape.com)
Amount of erythropoietin2
  • Only with a constant amount of erythropoietin, the synthesis of red blood cells is maintained at the required level. (sefuerte.info)
  • Erythropoietin replacement therapy may help boost red blood cell synthesis in the bone marrow if the amount of erythropoietin is low. (ultalabtests.com)
Hypoxia3
  • If the body experiences hypoxia (oxygen starvation), the synthesis of erythropoietin and, as a consequence, red blood cells, is dramatically accelerated to provide better oxygen transport. (sefuerte.info)
  • In response to hypoxia, HIF-1 activates the expression of many genes including vascular endothelial growth factor (VEGF) and erythropoietin. (cdc.gov)
  • The decrease in red cells predisposes the fetus to hypoxia, which elevates erythropoietin (EPO) levels. (jcnonweb.com)
Kidney7
  • Erythropoietin is a glycoprotein (about 30, 400 Daltons) that is produced primarily by the kidney and maintains red blood cell turnover. (southtees.nhs.uk)
  • The global erythropoietin biosimilar market for kidney diseases is expected to grow at a five year CAGR (2015-2020) of 23.8% to reach nearly $1.3 billion in 2020. (bccresearch.com)
  • Too many RBCs may be created if erythropoietin is produced in excess, as is the case with a number of different malignancies as well as some benign or malignant kidney tumors. (ultalabtests.com)
  • Erythropoietin is a substance produced by the kidney that leads to the formation of red blood cells in the bone marrow. (fastescrowrefills.net)
  • These cells release erythropoietin when the oxygen level is low in the kidney. (fastescrowrefills.net)
  • Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. (cdc.gov)
  • His research contributions included basic understanding of the pathophysiology and complications of advanced kidney disease, such as dialysis-associated amyloidosis, erythropoietin-stimulating agents in dialysis patients and structural abnormalities in patients with Alport syndrome and Goodpasture disease. (vumc.org)
Dialysis patients1
  • Treatment with recombinant human erythropoietin (rHu EPO) in dialysis patients has been shown to be highly effective in terms of correcting anaemia and improving quality of life. (qxmd.com)
Plasma erythropoietin1
  • Improved microbioassay for plasma erythropoietin based on CFU-E colony formation. (nii.ac.jp)
Release erythropoietin1
  • When blood oxygen levels are low, the kidneys generate and release erythropoietin into the blood. (ultalabtests.com)
Biosimilar erythropoietin2
  • This decline is due to both the expiry of major patented drugs and the entry of many biosimilar erythropoietin drugs in the European market, which are approximately 20% to 30% cheaper compared to patented drugs. (bccresearch.com)
  • Last month, CCM Duopharma Biotech (CCMDB) and PanGen Biotech announced the successful completion of a three-year, joint Phase III clinical trial for a biosimilar erythropoietin in South Korea and Malaysia. (bccresearch.com)
Polymorphisms2
  • Erythropoietin-producing Human Hepatocellular Carcinoma Receptor B1 Polymorphisms are Associated with HBV-infected Chronic Liver Disease and Hepatocellular Carcinoma in a Korean Population. (genominfo.org)
  • Associations between erythropoietin polymorphisms and risk of diabetic microvascular complications. (cdc.gov)
Hormone11
  • The erythropoietin test measures the amount of a hormone called erythropoietin (EPO) in blood. (medlineplus.gov)
  • Erythropoietin (EPO) is a moonlighting protein since is ability to work as hormone, cytokine and growth factor. (uniba.it)
  • Synthesis of erythrocytes in the blood is controlled by a special hormone, erythropoietin (EPO). (sefuerte.info)
  • Erythropoietin is a hormone of glycoprotein nature, which is synthesized by the kidneys. (sefuerte.info)
  • In the sports industry, the synthtic analogue of the hormone Erythropoietin in the form of a recombinant alpha isomer first appeared in 1987. (sefuerte.info)
  • Scientifically proven: the hormone erythropoietin, stimulating the formation of erythrocytes in the bone marrow, increases the working capacity of the body. (sefuerte.info)
  • The hormone called erythropoietin is largely produced by the kidneys. (ultalabtests.com)
  • Erythropoietin is produced and released at higher rates until blood oxygen levels return to normal or close to normal levels, at which point production of the hormone declines. (ultalabtests.com)
  • Erythropoietin (EPO) is a glycoprotein hormone synthesised predominately by the peritubular cells of the kidneys. (blood-academy.com)
  • This article briefly covers human growth hormone (hgh), erythropoietin (epo), and androgenic anabolic steroids and testosterone, and their potential for. (malsaralk.com)
  • so do anabolic steroids, human growth hormone (hgh), synthetic erythropoietin (epo), and countless other drugs classified loosely and. (malsaralk.com)
Preterm infants1
  • A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. (uams.edu)
Injection1
  • However, injection of GDPβS blocked the erythropoietin-induced calcium increase, providing direct evidence that activation of a G-protein is required. (elsevier.com)
Human12
  • The clinical development of recombinant human erythropoietin (rHuEPO) has had a remarkable impact on the clinical practice of oncology. (cancernetwork.com)
  • Erythropoietin induces a dose-dependent increase in cytosolic calcium in human erythroblasts that is mediated by a voltage-independent Ca 2+ channel. (elsevier.com)
  • The role of G-proteins in regulation of the erythropoietin-modulated Ca 2+ channel was delineated here by microinjection of G-protein modulators or subunits into human erythroid precursors. (elsevier.com)
  • In this study, it is hypothesized that a planned increase in the dose of recombinant human erythropoietin (rh-EPO) can prevent transfusion in very low birth weight infants. (unige.ch)
  • Here, we report positive outcomes following the use of recombinant human erythropoietin (EPO) as an adjuvant therapy in a case of severe COVID-19 infection. (panafrican-med-journal.com)
  • Erythropoietin, which is made naturally in the human body (i.e., biologic ), can also be made synthetically (i.e., biosimilar ). (bccresearch.com)
  • Erythropoietin and erythropoietin receptor expression in human cancer. (edu.pl)
  • Putative oncogenic role of the erythropoietin receptor in murine and human erythroleukemia cells. (edu.pl)
  • Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models. (edu.pl)
  • Erythropoietin-producing human hepatocellular carcinoma receptor B1 (EPHB1) is a member of the Eph family of receptor tyrosine kinases that mediate vascular system development. (genominfo.org)
  • Rat Erythropoietin was cloned in 1992, and it has a 79% and 95% homology with human and mouse EPOs, respectively. (biolegend.com)
  • I confirmed the effect of erythropoietin (Epo) on red cell size in human volunteers, whose mean corpuscular volume (MCV) increases following Epo administration. (umassmed.edu)
Patients7
  • Material and methods: In this prospective, observational, multicentric post marketing surveillance, adult CKD patients treated with erythropoietin were enrolled from November 2015 to December 2016 to understand their opinions about Wepox Pen TM . (scirp.org)
  • A total of 230 (98.7%) patients said that they would prefer to use erythropoietin pen device for further treatment too. (scirp.org)
  • Effect of erythropoietin therapy on polyneuropathy in predialytic patients. (semanticscholar.org)
  • Thirty-four patients were randomized into group 1 (systemic erythropoietin), group 2 (oral steroids), and group 3 (control). (preprints.org)
  • Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double- blind, placebo-controlled trial. (edu.pl)
  • Une anémie a été diagnostiquée chez 75 patients (37,5 %) en tout : 45 avaient une anémie hypochrome microcytaire, 18 une anémie normochrome normocytaire et 12 une anémie hyperchrome macrocytaire. (who.int)
  • Sur les 75 patients, 41 (54,7 %) avaient une carence en fer, 14 (18,7 %) avaient une carence en folates et 14 (18,7 %) avaient une thalassémie mineure. (who.int)
Biologic1
  • Erythropoietin biosimilars may be sold after a branded erythropoietin biologic product loses its patent protection. (bccresearch.com)
Rs16176401
  • The Erythropoietin Promoter Variant rs1617640 Is Not Associated with Severe Retinopathy of Prematurity, Independent of Treatment with Erythropoietin. (bvsalud.org)
Therapy2
  • Candidates for erythropoietin replacement therapy can be found with its aid. (ultalabtests.com)
  • Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis. (bvsalud.org)
Gene2
  • JAK2 V617F is known to activate some signaling pathways not normally activated in mature erythroblasts, but there has been no systematic study of signal transduction pathways or gene expression in erythroid cells expressing JAK2 V617F undergoing erythropoietin (Epo)-dependent terminal differentiation. (elsevier.com)
  • Regulation of the erythropoietin gene. (ox.ac.uk)
Darbepoetin1
  • In-depth testing done at the trainers' request determined in December that the four horses were negative for the performance-enhancing drugs erythropoietin or darbepoetin. (wordpress.com)
Apoptosis2
  • Although erythropoietin was demonstrated to have neuroprotective effects in neurodegenerative diseases, the effects of EPO on glucose‐evoked oxidative stress and apoptosis of SCs remain unknown. (semanticscholar.org)
  • It has been recently demonstrated that erythropoietin (EPO) attenuates apoptosis of ganglion cells. (egms.de)
Oxygen1
  • The kidneys' capacity to manufacture erythropoietin and the oxygen saturation level determine how much of it is released. (ultalabtests.com)
20161
  • 2016. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545068/all/Erythropoietin. (hopkinsguides.com)
Antibody3
  • The microtiter plate provided in this kit has been pre-coated with an antibody specific to Erythropoietin (EPO). (uscnk.com)
  • Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Erythropoietin (EPO). (uscnk.com)
  • After TMB substrate solution is added, only those wells that contain Erythropoietin (EPO), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. (uscnk.com)
Bone2
  • Datta, Asoke G. (1987) Effect of erythropoietin on the glucose transport of rat erythrocytes and bone marrow cells Biochemical Medicine and Metabolic Biology, 38 (2). (ias.ac.in)
  • Rarely, polycythemia is brought on by the bone marrow condition polycythemia vera rather than by an excess of erythropoietin. (ultalabtests.com)
20203
  • More specifically, the erythropoietin biologics segment is expected to decline at a five-year (2015-2020) CAGR of −4.1% to $5.3 billion in 2020. (bccresearch.com)
  • The erythropoietin biosimilars segment is expected to grow at a five-year CAGR of 23.2% to reach $2 billion in 2020. (bccresearch.com)
  • The Asia-Pacific region is predicted to account for one-third of the global erythropoietin biosimilars market by 2020. (bccresearch.com)
Effect4
  • Erythropoietin has only a minor protective effect on survival of SGC. (egms.de)
  • Pakravan, M. The Effect of Systemic Erythropoietin and Oral prednisolone on Recent-Onset Non-Arteritic Anterior Ischemic Optic Neuropathy: A Randomized Clinical Trial. (preprints.org)
  • To evaluate the effect of systemic erythropoietin, as well as oral steroids, in the management of recent onset non-arteritic anterior ischemic optic neuropathy (NAION). (preprints.org)
  • Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial. (who.int)
Assay3
  • This assay has high sensitivity and excellent specificity for detection of Erythropoietin (EPO). (uscnk.com)
  • Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Erythropoietin (EPO) were tested 20 times on one plate, respectively. (uscnk.com)
  • Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Erythropoietin (EPO) were tested on 3 different plates, 8 replicates in each plate. (uscnk.com)
Response6
  • So if one looked at them, one's got duplicate, triplicate examples over time, the first observation was totally surprising to me, that, that age and haemoglobin are independent variables for erythropoietin response. (webofstories.com)
  • And then if you start to draw erythropoietin response curves at different haemoglobin levels, they seem to be age dependent. (webofstories.com)
  • So if you've got five grams of haemoglobin at the age of two years, on average your erythropoietin response will be much higher than if you've got five grams of haemoglobin at five years, and that's the thing that's just seen the light of day in the PNAS. (webofstories.com)
  • Inhibition of this response to erythropoietin by pertussis toxin suggests involvement of guanine nucleotide-binding regulatory proteins (G-proteins). (elsevier.com)
  • Transducin βγ, but not α, subunits eliminated the calcium response to erythropoietin, demonstrating the primary role of the α subunit. (elsevier.com)
  • This was confirmed by the ability of microinjected recombinant myristoylated Giα2, but not Giα1 or Giα3 subunits, to reconstitute the response of pertussis toxin-treated erythroblasts to erythropoietin. (elsevier.com)
Cells3
  • This is the first report on the use of microinjection to study erythropoietin signal transduction in normal precursor cells. (elsevier.com)
  • These data directly demonstrate a physiologic function of G- proteins in hematopoietic cells and show that Giα2 is required in erythropoietin modulation of [Ca(i)] via influx through calcium channels. (elsevier.com)
  • Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. (edu.pl)
Anemic1
  • However, if a person has damaged kidneys and does not produce enough erythropoietin, too few RBCs are created and the person usually becomes anemic. (ultalabtests.com)
Levels2
India1
  • The anticipated entry of biosimilars in the US market and an increasing demand for erythropoietin biosimilars, particularly in developing countries such as India and China, will drive this growth. (bccresearch.com)
Blood1
Products1
  • BCC Research projects that over the next five years, the global market for erythropoietin biosimilars will continue to enjoy healthy gains while the global market for erythropoietin biologics (i.e., patented products) will shrink substantially. (bccresearch.com)
Survival1
  • The erythropoietin receptor (EpoR) is essential for erythroblast survival, but its other functions are not well characterized. (umassmed.edu)